AU760020B2 - Novel angiogenesis inhibitors - Google Patents
Novel angiogenesis inhibitors Download PDFInfo
- Publication number
- AU760020B2 AU760020B2 AU30789/99A AU3078999A AU760020B2 AU 760020 B2 AU760020 B2 AU 760020B2 AU 30789/99 A AU30789/99 A AU 30789/99A AU 3078999 A AU3078999 A AU 3078999A AU 760020 B2 AU760020 B2 AU 760020B2
- Authority
- AU
- Australia
- Prior art keywords
- benzoimidazol
- phenyl
- alkyl
- pyridin
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Description
WO 00/12089 PCT/US99/05297 TITLE OF THE INVENTION NOVEL ANGIOGENESIS INHIBITORS BACKGROUND OF THE INVENTION Tyrosine kinases are a class of enzymes that catalyze the transfer of the terminal phosphate of adenosine triphospate to tyrosine residues in protein substrates. Tyrosine kinases are believed, by way of substrate phosphorylation, to play critical roles in signal transduction for a number of cell functions. Though the exact mechanisms of signal transduction is still unclear, tyrosine kinases have been shown to be important contributing factors in cell proliferation, carcinogenesis and cell differentiation. Accordingly, inhibitors of these tyrosine kinases are useful for the prevention and treatment chemotherapy of proliferative diseases dependent on these enzymes.
For example, a method of treatment described herein relates to neoangiogenesis. Neoangiogenesis occurs in conjunction with tumor growth and in certain diseases of the eye. It is characterized by excessive activity of vascular endothelial growth factor.
Vascular endothelial growth factor (VEGF) binds the high affinity membrane-spanning tyrosine kinase receptors KDR and Flt-1.
Cell culture and gene knockout experiments indicate that each receptor contributes to different aspects of angiogenesis. KDR mediates the mitogenic function of VEGF whereas Fit-1 appears to modulate nonmitogenic functions such as those associated with cellular adhesion.
Inhibiting KDR thus modulates the level of mitogenic VEGF activity.
Vascular growth in the retina leads to visual degeneration culminating in blindness. VEGF accounts for most of the angiogenic activity produced in or near the retina in diabetic retinopathy. Ocular VEGF mRNA and protein are elevated by conditions such as retinal vein occlusion in primates and decreased pO2 levels in mice that lead to neovascularization. Intraocular injections of anti-VEGF monoclonal antibodies or VEGF receptor immunofusions inhibit ocular neovascularization in both primate and rodent models. Regardless of the WO 00/12089 PCT/US99/05297 cause of induction of VEGF in human diabetic retinopathy, inhibition of ocular VEGF is useful in treating the disease.
Expression of VEGF is also significantly increased in hypoxic regions of animal and human tumors adjacent to areas of necrosis. Monoclonal anti-VEGF antibodies inhibit the growth of human tumors in nude mice. Although these same tumor cells continue to express VEGF in culture, the antibodies do not diminish their mitotic rate. Thus tumor-derived VEGF does not function as an autocrine mitogenic factor. Therefore, VEGF contributes to tumor growth in vivo by promoting angiogenesis through its paracrine vascular endothelial cell chemotactic and mitogenic activities. These monoclonal antibodies also inhibit the growth of typically less well vascularized human colon cancers in athymic mice and decrease the number of tumors arising from inoculated cells. Viral expression of a VEGF-binding construct of Flk-1, the mouse KDR receptor homologue, truncated to eliminate the cytoplasmic tyrosine kinase domains but retaining a membrane anchor, virtually abolishes the growth of a transplantable glioblastoma in mice presumably by the dominant negative mechanism of heterodimer formation with membrane spanning endothelial cell VEGF receptors.
Embryonic stem cells, which normally grow as solid tumors in nude mice, do not produce detectable tumors if both VEGF alleles are knocked out. Taken together, these data indicate the role of VEGF in the growth of solid tumors. Inhibition of KDR or Flt-1 is implicated in pathological neoangiogenesis, and these are useful in the treatment of diseases in which neoangiogenesis is part of the overall pathology, e.g., diabetic retinal vascularization, as well as various forms of cancer.
Cancers which are treatable in accordance with the present invention demonstrate high levels of gene and protein expression.
Examples of such cancers include cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung. These include histiocytic lymphoma, lung adenocarcinoma and small cell lung cancers.
Additional examples include cancers in which overexpression or activation of Raf-activating oncogenes K-ras, erb-B) is observed.
-2- WO 00/12089 PCT/US99/05297 More particularly, such cancers include pancreatic and breast carcinoma.
The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as neoangiogenesis, cancer, atherosclerosis, diabetic retinopathy or inflammatory diseases, in mammals.
SUMMARY OF THE INVENTION A compound is disclosed in accordance with formula Ia:
.N
R2 or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein X is N or C;
RI&R
3 are independently H, Ci-o 1 alkyl, C 3 -6 cycloalkyl, Cs- 10 aryl, halo, OH, C 3 -10 heterocyclyl, or C 5 10 heteroaryl; said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; WO 00/12089 PCT/US99/05297
R
2 is
R
4
&R
5 are independently H, Cl-6 alkyl, C 5 1 0 aryl, C3-6 cycloalkyl, OH, NO 2
-NH
2 or halogen; independently H, Cl-o 1 alkyl, C3-6 cycloalkyl, C-.
6 alkoxy
C
2 -1 0 alkenyl, C2- 1 0 alkynyl, Cs 5 10 aryl, C 3 10 heterocyclyl,
C
1 -6 alkoxyNR 7
R
8 halo, NO 2 OH, -NH 2 or C_5 10 heteroaryl, said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra, or R4 and R5 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing one to three additional heteroatoms selected from the group consisting of N, O and S, which can be optionally substituted with from one to three members selected from R a Ra is R is
R
9 is H, Cllo 0 alkyl, halogen, NO 2 R, NHCI-6 alkylR 9 OR, -NR,
RNR
7 Rg, NR 7 Rs, R 7
R
8 CN, C 5 10 aryl, C 5 1 0 heteroaryl or
C
3 10 heterocyclyl; H, C 1 6 alkyl or Cl- 6 alkylR 9
C
5 1 0 aryl, C 3 10 heterocyclyl, or C 5 10 heteroaryl said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; and independently H, Cio 10 alkyl, C3-6 cycloalkyl, COR,
C
5 1 0 aryl, C 3 10 heterocyclyl, or C 5 10 heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R a or NR7R8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to R7&R8 are -4- WO 00/12089 PCT/US99/05297 two additional heteroatoms selected from the group consisting of N, 0 and S.
Further compounds are disclosed in accordance with formula I: or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein X is N or C; R, is H, Cl-1o alkyl, C 3 -6 cycloalkyl, C 5 1 0 aryl, halo, OH, C 3 1 0 heterocyclyl, or C 5 10 heteroaryl; said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra;
R
2
&R
3 are
R
4 is independently H, CI-6 alkyl, C 5 1 0 aryl, C3-6 cycloalkyl, OH, NO 2
-NH
2 or halogen; H, CI.-o alkyl, C3-6 cycloalkyl, C.-6 alkoxy C2- 10 alkenyl, C2- 1 0 alkynyl, Cs- 1 0 aryl, C 3 1 0 heterocyclyl, C 1 -6 alkoxyNR 7 Rg, NO 2 OH, -NH2 or C 5 10 heteroaryl, said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl WO 00/12089 PCT/US99/05297 R is Ra is R is
R
9 is being optionally substituted with from one to three members selected from Ra; H, or C,.
6 alkyl, OR, halo, NH 2 or NO 2 H, C 1 1 0 alkyl, halogen, NO 2 OR, -NR, NR 7
R
8
R
7 Rg,
C
5 10 aryl, Cs 5 10 heteroaryl or C 3 10 heterocyclyl; H, or C 1 6 alkyl, Ci- 6 alkylR 9
C
5 10 aryl, C 3 1 0 heterocyclyl, or C 5 10 heteroaryl; and independently H, Ci.lo alkyl, C3-6 cycloalkyl, COR,
C
5 10 aryl, C 3 10 heterocyclyl, or C 5 10 heteroaryl or NR7R8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, O and S.
R7&R8 are Also disclosed is a pharmaceutical composition which is comprised of a compound represented by the formula I: WO 00/12089 PCT/US99/05297 wherein R 1
R
2
R
3
R
4 and R 5 are described as above or a pharmaceutically acceptable salt or hydrate or prodrug thereof in combination with a carrier.
Also included is a method of treating or preventing a tyrosine kinase dependent disease or condition in a mammal which comprises administering to a mammalian patient in need of such treatment a tyrosine kinase dependent disease or condition treating amount of a compound of formula I or a pharmaceutically acceptable salt, hydrate or pro-drug thereof Also included is a method of treating or preventing cancer in a mammalian patient in need of such treatment which is comprised of admininstering to said patient an anti-cancer effective amount of a compound of formula I or a pharmaceutically acceptable salt, hydrate or pro-drug thereof.
Also included in the present invention is a method of treating or preventing diseases in which neoangiogenesis is implicated, which is comprised of administering to a mammalian patient in need of such treatment a compound of formula I or a pharmaceutically acceptable salt, hydrate or pro-drug thereof in an amount which is effective for reducing neoangiogenesis.
More particularly, a method of treating or preventing ocular disease in which neoangiogenesis occurs is included herein, which is comprised of administering to a mammalian patient in need of such treatment a compound of formula I or a pharmaceutically acceptable salt hydrate or pro-drug thereof in an amount which is effective for treating said ocular disease.
More particularly, a method of treating or preventing retinal vascularization is included herein, which is comprised of administering to a mammalian patient in need of such treatment a compound of formula I or a pharmaceutically acceptable salt, hydrate or pro-drug thereof in an amount which is effective for treating retinal vascularization. Diabetic retinopathy is an example of a disease in which neoangiogenesis or retinal vascularization is part of the overall disease etiology. Also WO 00/12089 PCT/US99/05297 included is a method of treating or preventing age-related macular degeneration.
These and other aspects of the invention will be apparent from the teachings contained herein.
DETAILED DESCRIPTION OF THE INVENTION The invention is described herein in detail using the terms defined below unless otherwise specified.
The term "alkyl" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 10 carbon atoms unless otherwise defined. It may be straight, branched or cyclic.
Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cycloheptyl, cyclopentyl and cyclohexyl.
Alkyl also includes a straight or branched alkyl group which contains or is interrupted by a cycloalkylene portion. Examples include the following: and -(CH 2 w
(CH
2 )z
(CH
2
(CH-
2 w herein: x plus y from 0-10; and w plus z from 0-9.
The alkylene and monovalent alkyl portion(s) of the alkyl group can be attached at any available point of attachment to the cycloalkylene portion.
When substituted alkyl is present, this refers to a straight, branched or cyclic alkyl group as defined above, substituted with 1-3 groups of Ra, described herein.
The term "alkenyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic (non-resonating) WO 00/12089 PCT/US99/05297 carbon-carbon double bonds may be present. Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted with one to three groups of Ra, when a substituted alkenyl group is provided.
The term "alkynyl" refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present. Preferred alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted with 1-3 groups of R a when a substituted alkynyl group is provided.
Aryl refers to 5-10 membered aromatic rings phenyl, substituted phenyl and like groups as well as rings which are fused, e.g., naphthyl and the like. Aryl thus contains at least one ring having at least atoms, with up to two such rings being present, containing up to atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms. The preferred aryl groups are phenyl and naphthyl. Aryl groups may likewise be substituted with 1-3 groups of Ra as defined herein. Preferred substituted aryls include phenyl and naphthyl substituted with one or two groups.
The term heterocycle, heteroaryl, heterocyclyl or heterocyclic, as used herein except where noted, represents a stable to 7-membered mono- or bicyclic or stable 7- to 10-membered bicyclic heterocyclic ring system, any ring of which may be saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. The heterocycle, heteroaryl or heterocyclic may be -9- WO 00/12089 PCT/US99/05297 substituted with 1-3 groups of Ra. Examples of such heterocyclic elements, inclusive of all possible isomers, include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyrimidonyl, pyridinonyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thiophenyl, imidazopyridinyl, tetrazolyl, triazinyl, thienyl, benzothienyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl.
The term "alkoxy" refers to those groups of the designated length in either a straight or branched configuration and if two or more carbon atoms in length, they may include a double or a triple bond.
Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy allyloxy, propargyloxy, and the like.
The term "halogen" is intended to include the halogen atom fluorine, chlorine, bromine and iodine.
The term "prodrug" refers to compounds which are drug precursors which, following administration and absorption, release the drug in vivo via some metabolic process. Exemplary prodrugs include acyl amides of the amino compounds of this inventon such as amides of alkanoic(Cl.6)acids, amides of aryl acids benzoic acid) and alkane(C.-6)dioic acids.
Tyrosine kinase dependent diseases or conditions refers to hyperproliferative disorders which are initiated/maintained by aberrant tyrosine kinase enzyme activity. Examples include psoriasis, cancer, immunoregulation (graft rejection), atherosclerosis, rheumatoid arthritis, angiogenesis tumor growth, diabetic retinopathy), etc.
One embodiment of the present invention is in accordance with formula Ia: 11 R3 R4R2 R1 Ia or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein X is N or C; R, is phenyl, thienyl, or thiazolyl, said phenyl, thienyl and thiazolyl is optionally substituted with one to three members selected from Ra;
R
3 is H, Cl,1o alkyl, C 36 cycloalkyl, Cslo aryl, halo, OH, C 310 heterocyclyl, or
C
5 1 o heteroaryl; said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R;
R
2 is independently H, C, 1 alkyl, C 5 10 aryl, C, 3 cycloalkyl, NO 2
-NH
2 or halogen;
R
4 is phenyl, pyridinyl, pyridinyl N-oxide, pyridinone, pyrimidinyl, or pyrimidinone, optionally substituted with one to three members selected from R;
R
5 is H, C,,o 1 alkyl, C 3 6 cycloalkyl, C,-6 alkoxy C2- 10 alkenyl, C2- 10 alkynyl, is C 5 1 0 aryl, C3- 1 o heterocyclyl, C, 6 alkoxyNR 7
R
8 halo, NO 2 OH, -NH 2 or C5- 10 heteroaryl, 0. said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R 3 9 .9 [I:\DayLib\LIBXX]544692speci.doc:aak WO 00/12089 PCT/US99/05297 Ra is H, C.- 1 0 alkyl, halogen, NO 2 R, NHC-.
6 alkylR 9 OR, -NR
RNR
7 Rs, NR 7
R
8
R
7 Rs, CN, C 5 10 aryl, Cs 5 10 heteroaryl or
C
3 10 heterocyclyl; R is H, C.- 6 alkyl or C1- 6 alkylR 9
R
9 is C 5 1 0 aryl, C 3 o 10 heterocyclyl, or C 5 1 0 heteroaryl said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; and R7&R8 are independently H, Ci_-o alkyl, C3-6 cycloalkyl, COR,
C
5 1 0 aryl, C 3 1 0 heterocyclyl, or C 5 1 0 heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra or NR7R8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, O and S.
An aspect of this invention is described wherein X is C and all other variables are as described above.
Another aspect of this invention is described wherein X is N and all other variables are as described above.
Still another aspect of this invention is described wherein R 4 is Ci.o 1 alkyl, C 3 -6 cycloalkyl, C 5 1 0 aryl, C 5 1 0 heteroaryl, or C 3 0 heterocyclyl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R a and all other variables are as described above.
In yet another aspect, the invention is described wherein RI is Cl-o 1 alkyl, C- 5 .o aryl, C 3 10 heterocyclyl, or C 5 ,lo heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from -12- WO 00/12089 PCT/US99/05297one to three members selected from Ra and all other variables are as described above.
Another aspect of this invention is described wherein Ra is H, Cl-io alkyl, halogen, C1- 6 alkylR 9 CN, R, OR, NR, RNR 7 Rs, NR 7
R
8
R
7
R
8 and all other variables are as described above.
A preferred subset of compounds of the present invention is realized when:
R,&R
3 are independently H, C.lo alkyl, Cs- 1 0 aryl, C 3 1 0 heterocyclyl, or C- 5 .o heteroaryl; said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra;
R
2 is
R
4
&R
5 are invention is independently H, C 1 -6 alkyl, C 3 6 cycloalkyl, OH, or halogen; independently H, C.-lo alkyl, C 3 6 cycloalkyl, C 5 10 aryl, Cs- 10 heteroaryl, C 3 1 0 heterocyclyl, Ci- 6 alkoxyNR 7 Rg,
NO
2 OH, -NH 2 or said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; and all other variables are as described above.
Another preferred subset of compounds of the present realized when: independently Cs 5 1 0 aryl, C 3 1 0 heterocyclyl, or Cs 5 1 0 heteroaryl; said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; H or Ci.
6 alkyl; piperidinyl, piperazinyl, 2-oxopiperazinyl, 2oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, Ri&R 3 are R2 is
R
4 is 13- 14 pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyrimidonyl, pyridinonyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thiophenyl, imidazopyridinyl, tetrazolyl, triazinyl, thienyl, benzothienyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl optionally substituted with from one to three members selected from and all other variables are as described above.
Another embodiment of the invention is a compound in accordance with formula I:
R
3
N
R
5 xN R1
I
X is N or C; R, is phenyl, thienyl, or thiazolyl, said phenyl, thienyl and thiazolyl is optionally a Is substituted with one to three members selected from R; R AR3 are independently H, C 16 alkyl, C 5 10 aryl, C 3 6 cycloalkyl, OH, NO,
-NH
2 or halogen;
R
4 is phenyl, pyridinyl, pyridinyl N-oxide, pyridinone, pyrimidinyl, or a pyrimidinone, optionally substituted with one to three members selected from R; [1:\DayLib\LIBXX544692speci.doc:aak
R
5 is H, C 1 -6 alkyl, OR, halo, NH 2 or NO 2 Ra is H, C-o 1 0 alkyl, halogen, NO 2 R, OR, -NR, NR 7 Rs, R 7
R
8 Cs- 1 0 aryl, C5-10 heteroaryl or C3- 10 heterocyclyl, R is H, or C-.
6 alkyl, Ci-6 alkylR 9
R
9 is C5- 1 0 aryl, C3- 1 0 heterocyclyl, or C5- 1 0 heteroaryl; and R7&R are independently H, C.o 1 0 alkyl, C3-6 cycloalkyl, COR, Cs- 1 0 aryl, C3- 1 0 heterocyclyl, or Cs- 1 0 heteroaryl or NR 7
R
8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, to O and S.
An aspect of this invention is described wherein X is C and all other variables are as described above.
Another aspect of this invention is described wherein X is N and all other variables are as described above.
Still another aspect of this invention is described wherein R 4 is C-o 10 alkyl, C3- 6 cycloalkyl, C5- 1 0 aryl, C5- 1 0 heteroaryl, or C 3 1 0 heterocyclyl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra and all other variables are as described above.
In yet another aspect, the invention is described wherein R, is C-lo 0 alkyl, Cs- 1 0 aryl, C3- 10 heterocyclyl, or C5- 1 0 heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from o [1:\DayLib\LIBXX]544692speci.doc:aak WO 00/12089 PCT/US99/05297 one to three members selected from Ra and all other variables are as described above.
A prefered embodiment of this invention is realized when: R, is
R
2
&R
3 are
R
4 is H, C 1 ,o 1 alkyl, C 5 10 aryl, C 3 10 heterocyclyl, or C 5 10 heteroaryl; said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; independently H, Cl-6 alkyl, C 3 -6 cycloalkyl, OH, or halogen; H, C.llo alkyl, C 3 -6 cycloalkyl, C 5 10 aryl, C 5 10 heteroaryl, C 3 1 0 heterocyclyl, C1.
6 alkoxyNR 7 Rs, NO 2 OH, -NH 2 or said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; and all other variables are as described above.
Another prefered embodiment of this invention is realized when:
R
1 is C 5 10 aryl, C_ 3 10 heterocyclyl, or Cs 5 10 heteroaryl; said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra;
R
2
&R
3 are independently H or C.-6 alkyl;
R
4 is Ci_ 10 alkyl, C 5 10 aryl, C 5 1 0 heteroaryl, C 3 1 0 heterocyclyl said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; and all other variables are as described above.
Still another embodiment of the invention is a compound in with formula IIa: accordance -16- 17 RiN R3' W
N
R
Ila or a pharmnaceutically acceptable salt, hydrate or prodrug thereof, wherein X W are independently N or C; R, is phenyl, thienyl, or thiazolyl, said phenyl, thienyl and thiazolyl is optionally a substituted with one to three members selected from R
R
3 is H, C -10 alkyl, C 3 6 cycloalkyl, C 5 10 aryl, halo, OH, C 3 10 heterocyclyl, or
C
5 10 heteroaryl; said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being i0 optionally substituted with from one to three members selected from R a;
R
2 is independently H, C 1 6 alkyl, C 5 10 aryl, C 3 6 cycloalkyl, OH, NO 2 -Ni 2 or halogen;
R
5 is H, C 1 10 alkyl, C 3 6 cycloalkyl, C 1 6 alkoxy C 2 10 alkenyl, C2- 0 alkynyl,
C
5 10 aryl, C 3 1 0 heterocyclyl, C,- 6 alkoxyNR 7
R
8 halo, NO 2 OH, -NH 2 or C 5 1 0 heteroaryl, said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra Rio is H, or C 16 alkyl, C 1 6 alkylR 9
C
5 1 o aryl, C 3 1 o heterocyclyl, NHC 16 alkylR 9 said alkyl (where R is C. ST [1:\DayLib\LIBXX]544692speci.doc:aak WO 00/12089 PCT/US99/05297 C,-6 alkyl), aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; Ra is H, CI.
10 alkyl, halogen, NO 2 OR, -NR, RNR 7 Rs, NR 7
R
8
R
7
R
8 CN, C 5 1 0 aryl, C 5 10 heteroaryl or C 3 10 heterocyclyl; R is H, C-.
6 alkyl or C_-6 alkylRg;
R
9 is C5- 10 aryl, C 3 10 heterocyclyl, or C 5 10 heteroaryl said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; and R7&R8 are independently H, Ci_ 1 0 alkyl, C3-6 cycloalkyl, COR,
C
5 10 aryl, C 3 10 heterocyclyl, or C 5 10 heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra or NR7R8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, O and S.
An aspect of this invention is described wherein X or W independently are C and all other variables are as described above.
Another aspect of this invention is described wherein X or W are independently N and all other variables are as described above.
Still another aspect of this invention is described wherein Rio is H, Ci- 10 alkyl, C.- 6 alkylR 9
C
5 1 0 aryl, C5- 1 0 heteroaryl, or C 3 1 0 heterocyclyl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra and all other variables are as described above.
18- WO 00/12089 WO 0012089PCT/US99/05297 Examples of the compounds of this invention are: 1) 1 -phenyl-5 -(4-methoxyphenyl)benzimidazole, 2) 1 -phenyl-5-(4-(2-( 1-piperidinyl)ethoxy)phenyl)benzimidazole, 3) 3 -phenyl-6-(4-methoxylphenyl)imidazo[4 ,5 -b]pyridine, 4) 3 -phenyl-6-(4-(2-( 1-piperidinyl)ethoxy)phenyl)imidazo [4,5 -b]pyridine, 3 -phenyl-6-(4-(2-( 1 -piperidinyl)ethoxyphenyl)imidazo 5-b]pyri dine, 6) 3-(2-thiazoyl)-6-(4-(3-( 1-piperidinyl)propylphenyl)imidazo[4,5b]pyridine, 7) 1 -(2-thiazoyl)-5 -piperidinyl)propyl)phenyl)benzimidazole, 8) 1 -thiophenyl)-5 -piperidinyl)propyl)phenyl)imidazo [4,5 b]pyridine, 9) 1 -thlophenyl)-5-(4-(3 -piperidinyl)propyl)phenyl)benzimidazole, 3 -(3-thlophenyl)-6-(4-(3 -piperidinyl)propylphenyl)imidazo[4,5 blpyridine, 11) 1 -Phenyl-5-[5-(2-piperidin- 1-yl-ethoxy)-pyridin-2-yl]- 1Hbenzimidazole, 12) 1 -(4-Cyanophenyl)-5- [6-(2-piperidin- 1-yl-ethoxy)-pyridin-3 -yI]-lHbenzimidazole, 13) 1 -Phenyl-5 -[6-(2-piperidin- 1-yl-ethoxy)-pyridin-3 -yl] -1Hbenzimidazole, 14) 1 -(3-Cyanophenyl)-5-[6-(2-piperidin- 1-yl-ethoxy)-pyridin-3-yl]- 1Hbenzimidazole, 1 -(3-Thiophene)-5- [6-(2-piperidin- 1-yl-ethoxy)-pyridin-3 -yl]-l Hbenzimidazole, 16) 1-Phenyl- 1H-benzoimidazol-5-yl)-pyridin-2-yl]-(2-piperidin- l-ylethyl)-amine, 17) 1-Phenyl- 1H-benzoimidazol-5-yl)-pyridin-2-yl]-(2-morpholin- 1yl-ethyl)-amine, 18) 1 -Pyridyl)-5 1-piperidinyl)ethoxy)phenyl)benzimidazole, 1 1-phenyl- 1H-benzoimidazol-5-yl)-l1-(3 -piperidin- 1-yl-propyl)- 1Hpyridin-2-one, 4-(l1-phenyl- 1H-benzoimidazol-5 -yl)-l -piperidin- 1-yl-ethyl)- 1Hpyridin-2-one, 19 WO 00/12089 PCTIUS99/05297 21) 1 -(2-morpholin-4-yl-ethyl)-4-( 1-phenyl- 1H-benzoimidazol-5-yl)- 1Hpyridin-2-one, 22) 1 -dimethylamino-propyl)-4-( 1-phenyl- 1H-benzoimidazol-5 -yl)-1 Hpyridin-2-one, 23) 1 -methyl-piperidin-3 -ylmethyl)-4-( 1-phenyl- 1H-benzoimidazol-5 yl)-l1 H-pyridin-2-one, 24) 1 -(4-methylpiperazin- 1-yl)-propyl)]-4-( 1-phenyl-l1H- 1H-pyridin-2-one, 1 -(2-dimethylamino-propyl)-4-( 1-phenyl- 1H-benzoimidazol-5-yl)-l1Hpyridin-2-one, 26) 1 -(3-dimethylamino-2-methyl-propyl)-4-( 1-phenyl- 1H- 1H-pyridin-2-one, 27) 1- [2-(4-cyano-piperidin- 1-yl)-ethyl]-4-(l1-phenyl- 1H-benzoimidazol- H-pyridin-2-one, 28) 1 -piperidin- 1-yl-propyl)-4-( 1-thiophen-3-yl- yl)-lI H-pyridin-2-one, 29) 1 -piperidin- 1-yl-ethyl)-4-( 1-thiophen-3 -yl-l H-benzoimidazol-5 -yl)- 1 H-pyridin-2-one, 1 -(2-morpholin-4-yl-ethyl)-4-( I-thiophen-3 -yl-l H-benzoimidazol- yl)-lI H-pyridin-2-one, 31) 1 -dimethylamino-propyl)-4-( 1-thiophen-3-yl- yl)-l H-pyridin-2-one, 32) 1 -methyl-piperidin-3-ylmethyl)-4-( 1-thiophen-3-yl- 1H- 1H-pyridin-2-one, 33) 1 -[3-(4-methylpiperazin- 1-yl)-propyl)]-4-( 1-thiophen-3-yl- 1H- 1H-pyridin-2-one, 34) 1 -(2-dimethylamino-propyl)-4-( 1-thiophen-3 -yl-l H-benzoimidazol-5 yl)-lI H-pyridin-2-one, 1 -dimethylamino-2-methyl-propyl)-4-( 1-thiophen-3 -yl-l Hbenzoimidazol-5-yl)- 1H-pyridin-2-one, 36) 1 -[2-(4-cyano-piperidin- 1-yl)-ethyl]-4-( 1-thiophen-3-yl- 1H- 1 H-pyridin-2-one, 37) 1-phenyl-l1H-benzoimidazol-5 -yl)-l -piperidin- 1-yl-propyl)- 1Hpyridin-2-one, 20 WO 00/12089 WO 0012089PCTfUS99/05297 38) 1-phenyl- 1H-benzoimidazol-5-yl)- 1-(3 -piperidin- 1-yl-ethyl)- 1Hpyridin-2-one, 39) 1 -(2-morpholin-4-yl-ethyl)-5-( 1-phenyl- 1H-benzoimidazol-5 -yl)-l Hpyridin-2-one, 40) 1 -(3-dimethylamino-propyl)-5-(l1-phenyl- 1H-benzoimidazol-5-yl)- 1Hpyridin-2-one, 41) 1 -methyl-piperidin-3-ylmethyl)-5-( 1-phenyl- Iyl)-lI H-pyridin-2-one, 42) 1 -(4-methylpiperazin-1I-yl)-propyl)]-5-( 1-phenyl- 1Hbenzoimidazol-5-yl)- 1 H-pyridin-2-one, 43) 1 -(2-dimethylamino-propyl)-5-( 1-phenyl- 1H-benzoimidazol-5-yl)- 1Hpyridin-2-one, 44) 1 -(3-dimethylamino-2-methyl-propyl)-5-( 1-phenyl-l1H- 1 H-pyridin-2 -one, 45) 1- [2-(4-cyano-piperidin- 1-yl)-ethyl]-5 -phenyl- 1H-benzoimidazol- H-pyridin-2-one, 46) 1 -(3-piperidin-1I-yl-propyl)-5-( 1-thiophen-3-yl- yl)-lI H-pyridin-2-one, 47) 1 -(3-piperidin- 1-yl-ethyl)-5-(l1-thiophen-3 -yl-l 1 H-pyridin-2-one, 48) 1 -(2-morpholin-4-yl-ethyl)-5-( 1-thiophen- 3-yl -1H-benzoimidazol- yl)-lI H-pyridin-2-one, 49) 1 -dimethylamino-propyl)-5 -thiophen-3 -yl-l H-benzoimidazol-5 yl)-l H-pyridin-2-one, 50) 1 -methyl-piperidin-3-ylmethyl)-5 -thiophen-3-ylI1Hbenzoimidazol-5-yl)-l1H-pyridin-2-one, 51) 1 -[3-(4-methylpiperazin- 1-yl)-propyl)]-5-( 1-thiophen-3-yl- 1Hbenzoimidazol-5-yl)-l1H-pyridin-2-one, 52) 1 -(2-dimethylamino-propyl)-5 -thiophen-3 -yl-l yl)-l H-pyridin-2-one, 53) 1 -dimethylamino-2-methyl-propyl)-5 -thiophen-3 -yl-l H- 1H-pyridin-2-one, 54) 1 -[2-(4-cyano-piperidin- 1-yl)-ethyl]-5-( 1-thiophen-3-yl-l1H- -yl)-l H-pyridin-2-one, 21 WO 00/12089 WO 00/ 2089PCT/US99/05297 5 -phenyl- 1H-benzoimidazol-5 -yl)-l -piperidin- 1-yl-propyl)- 1Hpyrimidin-2-one, 56) 1-phenyl- 1H-benzoimidazol-5-yl)- 1-(3-piperidin- 1-yl-ethyl)- 1Hpyrimidin-2-one, 57) 1 -(2-morpholin-4-yl-ethyl)-5-( 1-phenyl- 1H-benzoimidazol-5-yl)-l1Hpyrimidin-2-one, 58) 1 -dimethylamino-propyl)-5 -phenyl- 1H-benzoimidazol-5 -yl)-l Hpyrimidin-2-one, 59) 1 -methyl-piperidin-3 -ylmethyl)-5-( 1-phenyl- 1H-benzoimidazol- yl)-l H-pyrimidin-2-one, 1 -(4-methylpiperazin- 1-yl)-propyl)]-5-( 1-phenyl- 1H- 1H-pyrimidin-2-one, 61) 1 -(2-dimethylamino-propyl)-5-( 1-phenyl-l1H-benzoimidazol-5-yl)- 1Hpyrimidin-2-one, 62) 1 -dimethylamino-2-methyl-propyl)-5 -phenyl- 1H- -yl)-l H-pyrimidin-2-one, 63) 1- [2-(4-cyano-piperidin- 1-yl)-ethyl] -5 -(1-phenyl- IH-benzoimidazol- H-pyrimidin-2-one, 64) 1 -(3-piperidin- 1-yl-propyl)-5-( 1-thiophen-3-yl- yl)-l H-pyrimidin-2-one, 1 -(3-piperidin- 1-yl-ethyl)-5-(1 -thiophen-3-yl- 1 H-pyrimidin-2-one, 66) 1 -(2-morpholin-4-yl-ethyl)-5-( 1-thiophen-3-yl- yl)-l H-pyrimidin-2-one, 67) 1 -dimethylamino-propyl)-5 -thiophen-3 -yl-l H-benzoimidazol-5 yl)-l H-pyrimidin-2-one, 68) 1 -methyl-piperidin-3 -ylmethyl)-5 -thiophen-3 -yl-l H- -yl)-l H-pyrimidin-2-one, 69) 1 -13-(4-methylpiperazin- 1-yl)-propyl)]-5-( 1-thiophen-3-yl- 1Hbenzoimidazol-S-yl)-l1H-pyrimidin-2-one, 1 -(2-dimethylamino-propyl)-5-( 1-thiophen-3-yl- yl)-l H-pyrimidin-2-one, 71) 1 -(3-dimethylamino-2-methyl-propyl)-S-( 1-thiophen-3-yl- 1H- 1H-pyrimidin-2-one, 22 WO 00/12089 WO 00/ 2089PCTIUS99/05297 72) 1- [2-(4-cyano-piperidin- 1-yl)-ethyl]-5 -thiophen-3 -ylIH- 1H-pyrimidin-2-one, 73) 1-phenyl- 1H-benzoimidazol-5 -yl)-l -piperidin-l1-yl-propyl)- IHpyrimidin-2-one, 74) 1-phenyl- 1H-benzoimidazol-5-yl)- 1-(3-piperidin- 1-yl-ethyl)- 1Hpyrimidin-2-one, 1 -(2-morpholin-4-yl-ethyl)-4-( I-phenyl- 1H-benzoimidazol- 5-yl)-l Hpyrimidin-2-one, 76) 1 -dimethylamino-propyl)-4-( 1-phenyl- 1H-benzoimidazol-5 -yl)-l Hpyrimidin-2-one, 77) 1 -methyl-piperidin-3-ylmethyl)-4-( 1-phenyl- yl)-l H-pyrimidin-2-one, 78) 1- [3 -(4-methylpiperazin- 1-yl)-propyl)]-4-( 1-phenyl- 1H- 1H-pyrimidin-2-one, 79) 1 -(2-dimethylamino-propyl)-4-( 1-phenyl- 1H-benzoimidazol-5-yl)- 1Hpyrimidin-2-one, 1 -dimethylamino-2-methyl-propyl)-4- (1-phenyl- 1H- 1H-pyrimidin-2-one, 81) 1- [2-(4-cyano-piperidin- 1-yl)-ethyl] 1-phenyl- 1H-benzoimidazol- 5-yl)-l H-pyrimidin-2-one, 82) 1 -piperidin- 1-yl-propyl)-4-(l1-thiophen-3-yl- 1H-benzoimidazol-5 yl)-l H-pyrimidin-2-one 83) 1 -piperidin- 1-yl-ethyl)-4-( 1-thiophen-3 -yl-l 1 H-pyrimidin-2-one, 84) 1 -(2-morpholin-4-yl-ethyl)-4-( 1-thiophen-3-yl- yl)-l H-pyrimidin-2-one, 1 -dimethylamino-propyl)-4-( I-thiophen-3 -yl-l H-benzoimidazol-5 yl)-l H-pyrimidin-2-one, 86) 1 -methyl-piperidin-3-ylmethyl)-4-( 1-thiophen-3-yl- 1Hbenzoimidazol-5-yl)- 1H-pyrimidin-2-one, 87) 1 -[3-(4-methylpiperazin- 1-yl)-propyl)]-4-( 1-thiophen-3-yl- 1H- 1H-pyrimidin-2-one, 88) 1 -(2-dimethylamino-propyl)-4-(l1-thiophen-3-yl- yl)-l H-pyrimidin-2-one, 23 WO 00/12089 PCT/US99/05297 89) 1-(3-dimethylamino-2-methyl-propyl)-4-( -thiophen-3-yl-1Hbenzoimidazol-5-yl)-1 H-pyrimidin-2-one, 1-[2-(4-cyano-piperidin-1 -yl)-ethyl]-4-(1-thiophen-3-yl-l Hbenzoimidazol-5-yl)-1 H-pyrimidin-2-one, 91) 1-(4-Pyridyl)-5-(4-(2-(1-piperidinyl)ethoxy)phenyl)benzimidazole, 92) 1-(3-Pyridyl)-5-[6-(2-piperidin-1-yl-ethoxy)-pyridin-3-yl]-1Hbenzimidazole, and 93) 1-(4-Pyridyl)-5-[6-(2-piperidin-1-yl-ethoxy)-pyridin-3-yl]-1Hbenzimidazole or a pharmaceutically acceptable salt, hydrate or prodrug thereof.
The invention described herein includes a pharmaceutical composition which is comprised of a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof in combination with a carrier. As used herein the terms "pharmaceutically acceptable salts" and "hydrates" refer to those salts and hydrated forms of the compound which would be apparent to the pharmaceutical chemist, those which favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, which are also important in the selection, are the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug.
When a compound of formula I is present as a salt or hydrate which is non-pharmaceutically acceptable, this can be converted to a salt or hydrate form which is pharmaceutically acceptable in accordance with the present invention.
When the compound is negatively charged, it is balanced by a counterion, an alkali metal cation such as sodium or potassium.
Other suitable counterions include calcium, magnesium, zinc, ammonium, or alkylammonium cations such as tetramethylammonium, tetrabutylammonium, choline, triethylhydroammonium, meglumine, triethanolhydroammonium, etc. An appropriate number of counterions is associated with the molecule to maintain overall charge neutrality.
-24- WO 00/12089 PCT/US99/05297 Likewise when the compound is positively charged, protonated, an appropriate number of negatively charged counterions is present to maintain overall charge neutrality.
Pharmaceutically acceptable salts also include acid addition salts. Thus, the compound can be used in the form of salts derived from inorganic or organic acids or bases. Examples include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others. Other pharmaceutically acceptable salts include the sulfate salt ethanolate and sulfate salts.
The compounds of the present invention, may have asymmetric centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. When any variable aryl, heterocyle, R1, etc)occurs more than one time in any constituent or in Formula I, its definition on each occcurence is independent of its definition at every other occurrence, unless otherwise stated.
WO 00/12089 PCT/US99/05297 The compounds of the invention can be formulated in a pharmaceutical composition by combining the compound with a pharmaceutically acceptable carrier. Examples of such compositions and carriers are set forth below.
The compounds may be employed in powder or crystalline form, in solution or in suspension. They may be administered orally, parenterally (intravenously or intramuscularly), topically, transdermally or by inhalation.
Thus, the carrier employed may be, for example, either a solid or liquid. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Examples of liquid carriers include syrup, peanut oil, olive oil, water and the like. Similarly, the carrier for oral use may include time delay material well known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
Topical applications may be formulated in carriers such as hydrophobic or hydrophilic bases to form ointments, creams, lotions, in aqueous, oleaginous or alcoholic liquids to form paints or in dry diluents to form powders. Such topical formulations can be used to treat ocular diseases as well as inflammatory diseases such as rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reactions and the like.
Examples of oral solid dosage forms include tablets, capsules, troches, lozenges and the like. The size of the dosage form will vary widely, but preferably will be from about 25 mg to about 500mg. Examples of oral liquid dosage forms include solutions, suspensions, syrups, emulsions, soft gelatin capsules and the like.
Examples of injectable dosage forms include sterile injectable liquids, solutions, emulsions and suspensions. Examples of injectable solids would include powders which are reconstituted, dissolved or suspended in a liquid prior to injection.
In injectable compositions, the carrier is typically comprised of sterile water, saline or another injectable liquid, peanut oil for -26- WO 00/12089 PCT/US99/05297 intramuscular injections. Also, various buffering agents, preservatives and the like can be included.
For the methods of treatment disclosed herein, dosages can be varied depending upon the overall condition of the patient, the nature of the illness being treated and other factors. An example of a suitable oral dosage range is from about 0.1 to about 80 mg/kg per day, in single or divided doses. An example of a suitable parenteral dosage range is from about 0.1 to about 80 mg/kg per day, in single or divided dosages, administered by intravenous or intramuscular injection. An example of a topical dosage range is from about 0.1 mg to about 150 mg, applied externally from about one to four times a day. An example of an inhalation dosage range is from about 0.01 mg/kg to about 1 mg/kg per day.
The examples which follow illustrate the compounds that can be synthesized but they are not limited by the compounds in the tables nor by any particular substituents employed in the schemes for illustrative purposes.
The compounds may be administered in conventional dosages as a single agent or in combination with other therapeutically active compounds. The non-limiting examples that follow are illustrations of the compounds of the instant invention and are not meant to limit the invention in any way.
EXAMPLE 1 Br N NO 2 Br NO 2 rI N 2
NH
3 4 1-Bromo-4-fluoro-3-nitrobenzene (1.14 mL, 9.06 mmol) was dissolved in 5 mL of anhydrous 1-methyl-2-pyrrolidinone under argon. Aniline (0.870 mL, 9.55 mmol) was added followed by the addition of NN-diisopropylethylamine (1.90 mL, 10.9 mmol) and the resulting solution was heated to 120 oC. After 14 h additional aniline -27- WO 00/12089 PCT/US99/05297 (0.082 mL, 0.90 mmol) was added and heating was continued for 8 h.
The reaction solution was cooled to ambient temperature, diluted with water and extracted with ethyl acetate The combined extracts was washed with brine, dried over Na 2
SO
4 filtered and concentrated in vacuo to provide 4.
'H NMR (CDC13) 5 9.46 (bs, 1H), 8.35 1H, J= 2.4 Hz), 7.45-7.40 3H), 7.29-7.25 3H), 7.10 1H, J= 9.2 Hz).
MeO.
Br NO 2 NO 2 CNH NH 4 Bromoaromatic 4 (0.218 g, 0.744 mmol) and 4-methoxyboronic acid (0.125 g, 0.823 mmol) were dissolved in a mixture of dioxane (4 mL) and water (3 mL). Sodium carbonate (0.60 g, 5.7 mmol) was added and the resulting mixture was degassed and put under argon. Tetrakis(triphenylphosphine)palladium(0) (0.043 g, 0.037 mmol) was added and the reaction was heated to 80 oC. After 14 h the reaction was cooled to ambient temperature, diluted with water and extracted with ethyl actetate The combined extracts was dried with Na2SO4, filtered and concentrated to dryness. Purification by flash column chromatography (2 x 16 cm silica gel, 6:1 hexane/ethyl acetate) provided 'H NMR (CDC13) d 9.48 (bs, 1H), 8.40 1H, J 2.4 Hz), 7.58 (dd, 1H, J 2.4, 9.2 Hz), 7.50 2H, 9.0 Hz), 7.43 2H, J 9.0 Hz), 7.32-7.22 4H), 6.98 2H, J 9.0 Hz), 3.83 3H).
MeOw. MeO NNO2 N N NH -N 6 -28- WO 00/12089 PCT/US99/05297 1-phenyl-5-(4-methoxyphenyl)benzimidaole.
Nitroaniline 5 (0.213 g, 0.665 mmol) and palladium on carbon 100 mg) were stirred in 8 mL 3:1 EtOH/AcOH. The reaction was put under a balloon of H 2 After 2 h the reaction was filtered through a plug of celite and the filtrate was concentrated to dryness. The resulting residue was dissolved in 1.5 mL trimethylorthoformate and heated to 120 o C for 30 min. The solution was cooled concentrated to dryness and purified by flash column chromatography (2 x 15 cm silica gel, 1:1 hexane/ethyl acetate) which provided 6.
'H NMR (CDC1 3 5 8.14 1H), 8.04 1H, J= 0.9 Hz), 7.62-7.50 (m, 8H), 7.48 1H, J= 7.1 Hz), 7.01 2H, J= 8.8 Hz), 3.87 3H); FAB mass spectrometry [M+H] 301.1; Anal. Calcd. for C 20
H
16
N
2 0: C, 79.98; H, 5.37; N, 9.33. Found: C, 79.71; H, 5.48; N, 9.21.
MeO HO 6 7 An oven dried flask under argon was charged with benzimidazole 6 (0.039g, 0.13 mmol), aluminum chloride (0.175g, 1.31 mmol), and sodium iodide (0.200g, 1.33 mmol). Anhydrous acetonitrile (1 mL) and dichloromethane (0.5 mL) were added and reaction was heated to reflux. After 44 h the reaction was cooled to ambient temperature, quenched with water and extracted 3 x with ethyl acetate.
The combined extracts was dried over Na2SO 4 filtered and concentrated to dryness. The resulting residue was triturated with ether, filtered and dried to provide phenol 7.
-29- WO 00/12089 PCT/US99/05297 'H NMR (CDC1 3 8 9.48 1H), 8.58 1H), 7.93 1H), 7.73-7.71 2H), 7.67-7.63 3H), 7.57-7.49 4H), 6.86 2H, J= 8.6 Hz).
HO N 0N %^N 7 b 8 1-phenyl-5-(4-(2-(1 -piperidinyl)ethoxy)phenyl)benzimidazole Benzimidazole 7 (0.025g, 0.087 mmol) and N-(2chloroethyl)piperidine hydrochloride (11 mg, 0.059 mmol) were dissolved in anhydrous N,N-dimethylformamide (0.5 mL). Cesuim carbonate (0.085g, 0.26 mmol) was added and the resulting mixture was heated to 50 After 2 h additional and N-(2-chloroethyl)piperidine hydrochloride (11 mg, 0.059 mmol) was added. After 1 h the reaction was allowed to cool, quenched with water and extracted with ethyl acetate The combined extracts was washed with brine, dried over Na 2
SO
4 filtered and concentrated to dryness. Purification by flash column chromatography (2 x 16 cm silica gel, 9:1 CH 2
C
2 /MeOH) provided 8 as a colorless oil.
'H NMR (CDCl 3 8 8.14 1H), 8.03 1H, J= 0.9 Hz), 7.62-7.50 (m, 8H), 7.48 1H, J= 7.2 Hz), 7.01 2H, J= 8.8 Hz), 4.21 (bt, 2H, J= 5.3 Hz), 2.87 (bs, 2H), 2.59 (bs, 4H), 1.66 (bs, 4H), 1.48 (bs, 2H); Mass spectrometry 398.3.
EXAMPLE 2 Br ~NO 2 Br NO 2 "N OH 0 NH 6 WO 00/12089 PCT/US99/05297 5-Bromo-2-hydroxy-3-nitropyridine (5.736 g, 0.0262 mol) and 15mL thionyl chloride were added under argon. N,N dimethylformamide (1 mL) was then added and the solution was heated to reflux for 1 hr. By the end of the reaction, the bromohydroxynitropyridine was completely dissolved in solution. After cooling to ambient temperature, 5 mL of toluene was added, and the solution was concentrated under vacuum. The product, 5-bromo-2chloro-3-nitropyridine, was a yellow crystalline solid.
The bromochloronitropyridine was dissolved in 15mL of anhydrous 1-methyl-2-pyrrolidinone. Aniline (3.580 mL, 0.0393 mol) was added followed by the addition of N,N-diisopropylethylamine (13.69 mL, 0.0786 mol) and the solution was heated to 120 OC. After 1.5 hr., the solution was cooled to ambient temperature and diluted with water.
The product was extracted using ethyl acetate and washed with brine.
The organic layer was then dried over sodium sulfate, filtered, concentrated, and dried in vacuo. The crude mixture was purified using flash column chromatography (7.5 x 16 cm silica gel, 10:1 hexane:ethyl acetate) to afford 10 'H NMR (CDC13) 10.04 (bs, 1H), 8.65 (dd, 1H, J= 2.2 Hz), 8.50(dd, 1H, J =2.4 Hz), 7.60 2H, J=8.6 Hz), 7.40(t, 2H, J =7.5 Hz), 7.21 (t, 1H, J =7.3 Hz).
Br NO 2 MeO NH Y NO 2 N NH 1 11 Bromoaromatic 10 (30 mg, 0.102 mmol), 4methoxyphenylboronic acid (17 mg, 0.112 mmol) was dissolved in 0.75 mL dioxane followed by the addition of 204 gL of 2M sodium carbonate.
The vessel was flushed with argon followed by the addition of tetrakis(triphenylphosphine)palladium(0) (6 mg, 0.005 mmol) and 0.56 mL water. The vessel was flushed again with argon and heated to -31 WO 00/12089 PCT/US99/05297 °C for 2.5 hr. The solution was cooled to room temperature and diluted with water. The product was extracted with ethyl acetate and washed with brine, followed by drying over sodium sulfate. The organic layer was concentrated, and the product dried in vacuo. The crude mixture was purified by flash column chromatography (2.5 x 8 cm silica gel, 8:2 hexane:ethyl acetate), affording 11.
'H NMR (CDCl 3 5 10.09 (bs, 1H), 8.71 (dd, 1H, J =2.4 Hz), 8.66 (dd, 1H, J 7.67 2H, J 7.49 2H, J =8.8 Hz), 7.41 2H, J =7.7 Hz), 7.18 1H, J=7.3 Hz), 7.00 2H, J=8.6 Hz), 3.86 3H).
MeO MeO
SNO
2
N
N NH N
N
11 6 12 3-phenyl-6-(4-methoxylphenyl)imidazo[4,5-b]pyridine Nitroaniline 11 (1.333 g, 4.15 mmol), Zn dust(6.239 g, 95.40 mmol), and 10 mL acetic acid were mixed under argon. The solution was heated to 60 OC for 1 hr until the solution turned light green. The zinc was removed using vacuum filtration with celite and washed with acetic acid. The filtrate was concentrated and 20 mL of trimethylorthoformate was added. The solution was heated to 100 °C for 2 hr followed by cooling to ambient temperature. The solution was concentrated and the crude mixture was purified by flash column x 16 cm silica gel, 6:4 ethylacetate:hexane) affording 12.
'H NMR (CDC13) 6 8.61 (dd, 1H, J =2.0 Hz), 8.32 1H), 8.22 (dd, 1H, J 7.74 2H, J =7.9 Hz), 7.55-7.50 4H), 7.39 1H, J 6.99 2H, J =8.8 Hz), 3.80 3H). Mass spectrometry [M+H] 302.3.
-32- WO 00/12089 PCT/US99/05297 EXAMPLE 3 MeO HO N N N 12 13 To the imidazopyridine 12 (202 mg, 0.670 mmol) was added a mixture of 10 mL hydrobromic acid and 10 mL acetic acid. The solution was stirred a room temperature for 5 min., followed by heating at 100 °C for 17 hr. The solution was cooled to ambient temperature and concentrated. Toluene (15 mL) was added and the solution was concentrated a second time. The concentrate was placed in vacuo over heating at 40 °C for 40 min., followed by further drying in vacuo at ambient temperature. Purification was acheived by reverse phase column chromatography affording 13.
'H NMR (CD 3 OD) 5 9.45 1H), 8.82 (dd, 1H, J =1.8 Hz), 8.37 (dd, 1H, J=1.8 Hz), 7.91 2H, J=7.7 Hz), 7.68 2H, J=8.1 Hz), 7.63- 7.57 3H), 6.95 2H, J =8.6 Hz).
HO N- 0 N
N
13 N 14 N 3-phenyl-6-(4-(2-(1-piperidinyl)ethoxy)phenyl)imidazo[4,5-b]pyridine Cesium carbonate (296 mg, .908 mmol) and 1-(2chloroethyl)piperidine monochlorohyrdide (84 mg, .454 mmol) were added under argon to a flame dried round bottom flask. Imidazopyridine 13 (87 mg, .303 mmol) was dissolved in 1.5 mL of anhydrous N,N dimethyl formamide under argon. The vessel was heated at 50 oC for -33- WO 00/12089 PCT/US99/05297 16 hr. and cooled to ambient temperature. The solution was diluted to 100mL with saturated sodium bicarbonate, and the product was extracted using ethyl acetate. The aqueous layer was extracted a second time with dichloromethane w/ 3% 1-butanol. The organic layers were washed with saturated sodium bicarbonate, and dried over sodium sulfate. The organic layers were conentrated at aspirator pressure to remove ethyl acetate and methylene chloride; the 1-butanol and residual DMF were removed under high pressure. The product was purified using flash column chromatography(silica gel 2.5 x 32.5 cm, 10:1 methylene chloride:methanol). Excess trifluoroacetic acid was added to the product to create the resulting salt, and the mixture was triturated using ether. The TFA salt was dried using phosphorous pentoxide in vacuo to yield 14 (1.10 TFA salt).
'H NMR (CD30D) 6 8.66 1H), 8.55 (dd, 1H, J =2.0 Hz), 8.17 (dd, 1H, J=2.0 Hz), 7.82 2H, J =8.6 Hz), 7.59-7.52 4H), 7.46 1H, Hz), 7.01 2H, J=8.8 Hz), 4.85 2H), 4.15 2H, Hz), 2.84 2H, J =5.5 Hz), 2.62 (bs, 4H), 1.65 4H), 1.50 2H).
Anal. Calcd. for C 25
H
26
N
4 0*1.10 TFA: C, 62.35; H, 5.21; N, 10.69.
Found: C, 62.32; H, 4.93; N, 10.53.
EXAMPLE 4 Br 02 N
NH
4 Bromoaromatic 4 (7.10 g, 24.1 mmol) and powdered zinc (36.2 g, 554 mmol, 23 equiv) were stirred in 80 mL glacial acetic acid. The mixture was heated to 60 oC. After 1h the reaction was cooled and filtered through a plug of celite and concentrated to dryness. The resulting residue was dissolved in 60 mL of formic acid and heated to 100 °C overnight. The reaction was cooled and concentrated to dryness.
Purification by flash column chromatography (6x25 cm silica, 55:45 -34- WO 00/12089 PCT/US99/05297 hexanes/EtOAc) afforded 5.88 g benzimidazole 15 (89% yield). 'H NMR(CDC1 3 5 8.18 1H), 8.05 1H, J=1.7 Hz), 7.60 2H, J=7.1 Hz), 7.54-7.48 3H), 7.46 (dd, 1H, J= 1.8, 8.8 Hz), 7.40 1H, J=8.8 Hz).
F N r J Br 16 1-Piperidineethanol (1.13 mL, 8.51 mmol) was dissolved in 10 mL anhydrous DMF under Ar. The solution was cooled to 0 oC and NaH (225 mg, 9.38 mmol) was added. After 10 min the mixture was allowed to warm to room temperature and 5-bromo-2-fluoropyridine (1.50 g, 8.52 mmol) was added. After lh the reaction was quenched with water and extracted 3x with EtOAc. The combined extracts were dried over Na2SO4, filtered and concentrated to afford 2.20 g (91% yield) of the alkoxypyridine 16. 'H NMR(CDCl 3 8 8.17 1H, J=2.6 Hz), 7.62 (dd, 1H, J=2.6, 8.8 Hz), 6.67 1H, J=8.8 Hz), 4.40 2H, J=6.0 Hz), 2.74 2H, J=5.9 Hz), 2.49 4H), 1.60 4H), 1.44 2H).
Br
N
N o N 17 b 1 -Phenyl-5-[6-(2-piperidin-1 -yl-ethoxy)-pyridin-3 -yl]-1 H-benzimidazole Benzimidazole 15 (2.91 g, 10.7 mmol), diboron pinacol ester (2.97 g, 11.7 mmol) and potassium acetate (3.14 g, 32.0 mmol) were stirred in mL anhydrous DMF under Ar. PdCl 2 (dppf) (0.26 g, 0.32 mmol) was added, solution was degassed and heated to 80 After 20h the reaction was quenched with 125 mL of water and 50 mL of saturated aqueous NaCI and was extracted 3 x with EtOAc. The combined WO 00/12089 PCT/US99/05297 extracts were dried over Na 2
SO
4 filtered and concentrated to afford 2.77 g ofunpurified boronate. The unpurified boronate (650 mg, 2.03 mmol), alkoxypyridine 16 (526 mg, 1.85 mmol), 2M Na 2
CO
3 (861 mg, 8.12 mmol), and 4 mL dioxane were added to a round bottom flask.
After flushing three times with argon, Pd(PPh 3 4 (117 mg, 10 mmol) was added, and the vessel was again flushed three times with argon.
The vessel was heated to 80 OC under argon. After 22 hr., the reaction was cooled to room temperature followed by quenching with water. The mixture was extracted with 4x20 mL ethyl acetate, and the combined organic layers were washed with lx20mL brine. The organic layer was dried over sodium sulfate, filtered, and concentrated.
Purification was performed using reverse phase column chromatography (Waters 2x40mm C-18 column, H 2 0:acetonitrile mobile phase gradient).
The resulting oil was triturated with ether, filtered and washed with ether, affording 16, a white TFA salt(150 mg, 16% yield). Mp: 160.5 162 oC. 'H NMR(CDCl 3 8 8.41 1H, J=2.4 Hz), 8.19 1H), 8.01 1H, J=1.3 Hz), 7.90 (dd, 1H, J=11.0 Hz), 7.61 3H, J 7.52 4H, J =31.0 Hz), 6.86 1H, J =8.4 Hz), 4.79 2H, J =9.9 Hz), 3.76 (bd, 2H, J =11.9 Hz), 3.51 2H, J =9.7 Hz), 2.80 (bt, 2H, J =23.1 Hz), 2.06 2H, J =26.2 Hz), 1.89 2H), 1.65 2H).
-36- WO 00/12089 WO 0012089PCTIUS99/05297 EXAMPLE Pd(Ph 3
P)
4 /Dioxanc Na 2
CO
3 lLiCl B(OH)2 2
N
C2C03. Nal, DMF 1. AC 2 02 reflUX 2. NH 4 OH, MeOH 37 WO 00/12089 PCT/US99/05297 Steps (11) (13.4 g, 49.1 mmol), 4pyridylboronic acid (6.63 g, 54.0 mmol), palladium(II) acetate (551 mg, 2.45 mmol) and triphenylphosphine (1.93 g, 7.36 mmol) were stirred in mL of n-PrOH in a flask equipped with a reflux condenser, under Ar.
Sodium carbonate (6.24 g, 58.9 mmol) was dissolved in 30 mL of water and the resulting solution was added to the nPrOH mixture. The resulting mixture was degassed three times by alternating vacuum and argon atmoshphere. The reaction was then heated to reflux. After 18h the reaction as cooled, diluted with water and extracted three times with EtOAc. The combined extracts were washed with sat. NaCl dried over sodium sulfate, filtered and concentrated. Purification by flash column chromatography (95:5 CH 2 C1 2 /MeOH) afforded 8.82 g of 1phenyl-5-pyridin-4-yl-1H-benzoimidazole (66% yield).
1H NMR (CDC13) 5 8.68 6.0 Hz, 2H), 8.18 1H), 8.17 1H), 7.63-7.59 6H), 7.56-7.51 3H). Mass Spectrometry (for C18H13N3): 272.1182, theoretical 272.1182.
12 6 1-Phenyl-5-pyridin-4-yl-1H-benzoimidazole (12) (8.82 g, 32.5 mmol) was dissolved in 120 mL of CH 2 Cl 2 The resulting solution was cooled to 0°C and to it was added mCPBA (11.2 g, 65.0 mmol). After stirring for 2.5 days an additional portion ofmCPBA (3.0 g, 17 mmol) was added. After an additional 24 h the reaction solution was loaded directly -38- WO 00/12089 PCT/US99/05297 onto a column (8 x 20 cm) pre-wetted with CH 2 C12. The resulting flash column chromatography, eluting with 9:1 CH 2 Cl 2 /MeOH, afforded 7.40 g of 5-(1 -oxy-pyridin-4-yl)- -phenyl- 1H-benzoimidazole (13) (79% yield).
'H NMR (CDC13) 8 8.40 J= 6.0 Hz, 2H), 8.18 1H), 8.11 J 1.5 Hz, 1H), 7.66-7.47 9H). Mass Spectrometry (for Ci8HI 3
N
3 288.1131, theoretical 288.1131.
5-(1-Oxy-pyridin-4-yl)-1 -phenyl-1 H-benzoimidazole (13) 0 HN (7.40 g, 25.8 mmol) was stirred in 48.6 mL of acetic anhydride (52.6 g, 515 mmol) and the resulting mixture was heated to reflux. After 8h the reaction was concentrate to dryness and the resulting residue was dissolved in 50 mL MeOH. Concentrated ammonium hydroxide (10 mL) was added and the solution was stirred for 16h. The solution was then concentrated to dryness and the residue was purified by flash column chromatography (elute with 95:5-90:10 CH 2 C2/MeOH) to afford 4.57 g of 4-(1-phenyl- 1H-benzoimidazol-5-yl)- H-pyridin-2-one (14) (62% yield). 'H NMR (CDCl 3 11.59 (bs, 1H), 8.18 1H), 8.13 J= 0.9 Hz, 1H), 7.64-7.60 4H), 7.55-7.51 3H), 7.42 J= 7.0 Hz, 1H), 6.88 J 1.3 Hz, 1H), 6.65 (dd, J 1.8, 7.0 Hz, 1H). Elemental analysis (for 0.40 hydrate): Calc'd C, 73.40, H, 4.72, N, 14.27; Found C, 73.33, H, 5.00, N, 13.91.
4-(1-phenyl- 1H-benzoimidazol-5-yl)-1H-pyridin-2-one (14) -39- WO 00/12089 PCT/US99/05297 (4.57 g, 15.9 mmol) was dissolved in 30 mL anhydrous DMF under Ar.
Sodium iodide (2.86 g, 19.1 mmol), cesium carbonate (11.9 g, 36.6 mmol) and N-chloropropylpiperidine HCI salt (3.78 g, 19.1 mmol) were added and the reaction was warmed to 40°C. After 3 days additional portions of N-chloropropylpiperidine HCI salt (1.9 g, 9.6 mmol) and cesium carbonate (6.0 g, 18 mmol) were added. After an addtional 16 h the bulk of the DMF was removed in vacuo. The residue was diluted with water and extracted 3x with 5% n-BuOH in CH 2 C1 2 The combined organic phases was dried over Na 2
SO
4 filtered and concentrated. The residue was purified in several batches by preperative reverse phase HPLC, dissolving sample in MeOH, eluting with 5:95 acetonitrile/water H3P04) to 50:50. Fractions containing pure product were concentrated to remove the bulk of the acetonitrile, basified to pH 8 w/ Na 2
CO
3 and extracedt 3x with 5% BuOH in CH 2
C
2 The combined organic phases were dried over Na 2
SO
4 filtered and concentrated to afford 3.70g of pure 4-(1-phenyl-lH-benzoimidazol-5-yl)- 1 -(3-piperidin- 1-yl-propyl)-1H-pyridin-2-one 'H NMR (CDC13) 5 8.17 1H), 8.10 1H), 7.63-7.50 7H), 7.45 J= 7.1 Hz, 1H), 6.85 J= 1.6 Hz, 1H), 6.52 (dd, J= 1.8, 7.1 Hz, 1H), 4.05 J= 6.8 Hz, 2H), 2.38-2.34 4H), 2.00 J= 6.8 Hz, 2H), 1.65-1.58 6H), 1.45 2H). Elemental analysis: Calc'd C, 75.70, H, 6.84, N, 13.58; Found C, 75.32, H, 6.87, N, 13.37.
V
Q
Br N
OB
11 16 WO 00/12089 PCT/US99/05297 5-Bromo-l-phenyl-1H-benzoimidazole (11) (9.71 g, 35.6 mmol), diboron pinacol ester (9.93 g, 39.1 mmol), potassium acetate (10.5 g, 107 mmol) and dichloro[1,1 '-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.78 g, 1.1 mmol) were stirred in 40 mL anhydrous DMF under Ar. The solution was degassed three times by alternating vacuum and argon atmosphere. The reaction was heated to for 18h. After cooling the reaction was diluted with water and extracted 3x with EtOAc. The combined organic phases were dried over Na 2
SO
4 filtered and concentrated to afford 11.8 g 1-phenyl-5-(4,4,5,5tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-benzoimidazole (16) which was used without purification.
HO 0 17 18 Sodium hydride (0.073 g, 3.0 mmol) was stirred in 4 mL anhydrous DMF under Ar. The solution was cooled to 0°C and hydroxypyridine (0.305 g, 1.38 mmol) was added gradually. After bubbling had subsided N-chloropropylpiperidine hydrochloride (0.330 g, 1.67 mmol) was added slowly. The reaction was then allowed to warm to ambient temperature. After 40h the reaction was diluted with water and extracted 3x with EtOAc. The combined organic phases were washed was washed with saturated NaCl dried over Na 2
SO
4 filtered and concentrated. Purification by flash column chromatography (2 x 16 cm silica, 9:1 CH2C12/MeOH) afforded 192 mg 5-iodo-1-(3piperidin-1 -yl-propyl)- 1H-pyridin-2-one (18) (40% yield). 'H NMR (CDC13) 8 7.72 J 2.6 Hz, 1H), 7.40 (dd, J 2.6, 9.5 Hz, 1H), 6.37 J 9.5 Hz, 1H), 3.96 J 6.6 Hz, 2H), 2.35 (bs, 4H), 2.26 J 6.6 Hz, 2H), 1.92 6.6 Hz, 2H), 1.60 4H), 1.46 2H).
-41 WO 00/12089 PCT/US99/05297 0j 16 18 i9 5-iodo-1-(3-piperidin-1-yl-propyl)-1 H-pyridin-2-one (18) (0.096 g, 0.28 mmol), 1 -phenyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)- 1Hbenzoimidazole (0.081 g, 0.25 mmol), palladium(II) acetate (0.003 g, 0.013 mmol), triphenylphosphine (0.010 g, 0.038 mmol) and sodium carbonate (0,080 g, 0.75 mmol) were stirred in 1.6 mL of a 3:1 mixture of dioxane/water. The mixture was degassed 3x by alternating vacuum and an argon atmosphere. The reaction was heated to 80 0 C for 18h, cooled and diluted with water. The aqueous phase was extracted 3x with EtOAc and the resulting organic phase was dried over Na 2
SO
4 filtered and concentrated. Purification by flash column chromatography (eluted with 85:15 CH 2
CI
2 /MeOH) afforded 0.073 g 5-(1-phenyl-1H- -(3-piperidin-1-yl-propyl)-1 H-pyridin-2-one (19) (71% yield). 'H NMR (CDCl 3 8 9.60 1H), 7.90 J 1.3 Hz, 1H), 7.74-7.67 (min, 2H), 7.64-7.48 (min, 6H), 7.39 (dd, J 2.5, 9.5 Hz, 1H), 6.68 J 9.5 Hz, 1H), 4.13 J 6.5 Hz, 2H), 2.42 (bs, 6H), 2.10 (t, J 6.5 Hz, 2H), 1.64 4H), 1.46 (mn, 2H). Mass Spectrometry (for
C
26
H
28
N
4 413.2334, theoretical 413.2336.
+16 M S 21 To a flame dried round bottom flask with stir bar was added I (4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)- 1H-benzoimidazole (16) (2.00 g, 6.25 mmol), triphenylphosphine (147 mg,.562 mmol) palladium(II) acetate (42 mg, .187 mmol), 2M aqueous Na 2
CO
3 (9.37 mL, 18.7 mmol), 4-chloro-2-methylthiopyrimidine (1.00 g, 6.24 mmol), -42- WO 00/12089 PCT/US99/0529-7 3 mL water, and 14 mL of 1-propanol. Vessel was flushed three times with argon and placed in 80 oC oil bath with stirring. Reaction was complete after 1.7 hr by HPLC cooled to RT and removed solvent under vacuum. Workup included dissolution into 150 mL ethyl acetate, adding 50 mL 1/2 saturated aqueous NaHCO 3 extracting, then extracting the aqueous layer again with 2 x 40 mL EtOAc. Washed combined organics with 1 x 50 mL 1/2 saturated brine, dried over Na 2
SO
4 filtered, and concentrated under vacuum. Performed purification via flash column chromatography (60 mm x 200 mm silica gel, 20:1
CH
2 Cl 2 :MeOH mobile phase) to afford 1.54 g of compound (21) (77% yield). 'HNMR (CDC1 3 8 8.64 1H), 8.56 1H) 8.20 1H), 8.18 (dd, 1H), 7.63 3H), 7.53 3H), 7.47 1H), 2.68 3H).
M.O^ N 21 22 ^S/ To a stirred suspension of Oxone (potassium peroxymonosulfate, 11.87 g, 19.31 mmol) in water at 0 OC was added a suspension of the starting methyl sulfide benzimidazole (21) (1.54 g, 4.83 mmol) in MeOH. The reaction mixture was allowed to warm to RT and was monitored by HPLC. The starting methyl sulfide changed from the methyl sulfoxide to the methyl sulfone over the course of 12 hr. The MeOH was removed under vacuum after the reaction was complete. The reaction mixture was extracted with 3 x 40 mL CH 2 C12. The combined organic layers were washed with 40 mL brine, dried over Na 2
SO
4 filtered, and the solvent removed under vacuum to afford 1.5g (22) (90% crude yield).
'HNMR: (CDCl 3 8 8.92 1H, J= 5.3 Hz), 8.66 1H, J= 1.6 Hz), 8.27 (dd, 1H, J= 1.6, 7.1 Hz), 8.23 1H), 8.00 1H, J= 5.4 Hz), 7.65 3H), 7.54 3H), 3.47 3H).
-43- WO 00/12089 PCT/US99/05297 MeO2S^^" HO N 22 2 To a flask containing the starting methyl sulfone (500 mg, 1.427 mmol) was added 56% LiOH hydrate (244 mg, 5.708 mmol). To this vessel was added 5 mL tetrahydrofuran and 5 mL water. The reaction mixture was cooled to 0 oC for 2 hr, then gradually was allowed to warm to RT.
The reaction was stirred at RT overnight. The reaction was complete after 20 hr and the THF via low vacuum rotary evaporation and water by high vacuum rotary evaporation. The crude material was diluted in mL MeOH, sonicated, and filtered through cotton and a 0.7 gM syringe filter into round bottom flask. The filtrate was concentrated to afford 480 mg of unpurified product The solvent was again removed via rotary evaporation. 'H NMR: (CD30D) 8 8.47 1H), 8.40 1H), 8.20 1H, J=5.2 Hz), 8.07 (dd, 1H, J= 1.4, 7.3 Hz), 7.65 5H), 7.55 (m, 1H), 6.92 1H, J=5.3 Hz). High resolution mass spectometry: Measured mass 289.1068 (289.1084 theoretical mass).
To a flask containing the starting benzimidazole (23) (66 mg, .229 mmol) was added N-3-chloropiperidine HCI (54 mg, .275 mmol), cesium carbonate (164 mg, .504 mmol) and 4 mL anhydrous N,Ndimethylformamide. The vessel was placed in 60 "C oil bath with stirring under argon. The reaction was heated to 80 OC after 1 day, and was stopped after 4 days after no further progression. The solvent was removed via high vacuum rotary evaporation, the residue was diluted -44- WO 00/12089 PCT/US99/05297 with MeOH, and filtered through a 0.7 gM syringe filter. Reverse phase column chromatography (Waters 2x40mm C-18 stationary phase,
ACN:H
2 0 mobile phase gradientcontaining 1% TFA). Concentrated appropriate HPLC fractions to afford two distinct products confirmed to be N-alkylated and O-alkylated isomers by mass spectrometry (low res. M+1=414.3 and 'H NMR. Yields of the TFA salts were: Nalkylated (24) (38.6 mg, 32% yield), O-alkylated (not shown) (6.2 mg, yield). The 'HNMR for 4-(1-phenyl-1H-benzoimidazol-5-yl)- 1 piperidin-l-yl-propyl)-lH-pyrimidin-2-one is as follows: (CDC13) 8.63 1H, J= 7.9 Hz), 8.34 1H, J= 10.1Hz), 7.92 1H, J=6.9 Hz), 7.62 6H), 7.01 1H, J= 7.0 Hz), 4.11 2H, J= 7.0 Hz), 3.64 (m, 2H), 3.17 2H), 2.68 2H), 2.39 2H), 1.92 6H).
The following compounds can be made by literature methods and/or in combination with methods disclosed herein.
WO 00/12089 PCT/US99/05297 O n I iN N N N N
N
NG 0
N
N
N
Kinase inhibition is demonstrated in accordance with the following protocol.
VEGF RECEPTOR KINASE ASSAY VEGF receptor kinase activity is measured by incorporation of radio-labeled phosphate into polyglutamic acid, tyrosine, 4:1 (pEY) substrate. The phosphorylated pEY product is trapped onto a filter membrane and the incoporation of radio-labeled phosphate quantified by scintillation counting.
-46- WO 00/12089 PCT/US99/05297
MATERIALS
VEGF receptor kinase The intracellular tyrosine kinase domains of human KDR (Terman, B.I. et al. Oncogene (1991) vol. 6, pp. 1677-1683.) and Flt-1 (Shibuya, M. et al. Oncogene (1990) vol. 5, pp. 519-524) were cloned as glutathione S-transferase (GST) gene fusion proteins. This was accomplished by cloning the cytoplasmic domain of the KDR kinase as an in frame fusion at the carboxy terminus of the GST gene. Soluble recombinant GST-kinase domain fusion proteins were expressed in Spodoptera frugiperda (Sf21) insect cells (Invitrogen) using a baculovirus expression vector (pAcG2T, Pharmingen).
Lysis buffer mM Tris pH 7.4, 0.5 M NaC1, 5 mM DTT, 1 mM EDTA, 0.5% triton X-100, 10 glycerol, 10 mg/ml of each leupeptin, pepstatin and aprotinin and ImM phenylmethylsulfonyl fluoride (all Sigma).
Wash buffer 50 mM Tris pH 7.4, 0.5 M NaC1, 5 mM DTT, 1 mM EDTA, 0.05% triton X-100, 10 glycerol, 10 mg/ml of each leupeptin, pepstatin and aprotinin and 1mM phenylmethylsulfonyl fluoride.
Dialysis buffer mM Tris pH 7.4, 0.5 M NaC1, 5 mM DTT, 1 mM EDTA, 0.05% triton X-100, 50 glycerol, 10 mg/ml of each leupeptin, pepstatin and aprotinin and 1mM phenylmethylsuflonyl fluoride X reaction buffer 200 mM Tris, pH 7.4, 1.0 M NaC1, 50 mM MnC12, 10 mM DTT and 5 mg/ml bovine serum albumin (Sigma).
-47- WO 00/12089 PCT/US99/05297 Enzyme dilution buffer mM Tris, pH 7.4, 0.1 M NaCi, 1 mM DTT, 10 glycerol, 100 mg/ml BSA.
10 X Substrate 750 [ig/ml poly (glutamic acid, tyrosine; 4:1) (Sigma).
Stop solution trichloroacetic acid, 0.2 M sodium pyrophosphate (both Fisher).
Wash solution trichloroacetic acid, 0.2 M sodium pyrophosphate.
Filter plates Millipore #MAFC NOB, GF/C glass fiber 96 well plate.
METHOD
A. Protein purification 1. Sf21 cells were infected with recombinant virus at a multiplicity of infection of 5 virus particles/ cell and grown at 27 "C for 48 hours.
2. All steps were performed at 4 0 C. Infected cells were harvested by centrifugation at 1000 X g and lysed at 4 oC for 30 minutes with 1/10 volume of lysis buffer followed by centrifugation at 100,000Xg for 1 hour. The supernatant was then passed over a glutathione Sepharose column (Pharmacia) equilibrated in lysis buffer and washed with 5 volumes of the same buffer followed by 5 volumes of wash buffer. Recombinant GST-KDR protein was eluted with wash buffer/10 mM reduced glutathione (Sigma) and dialyzed against dialysis buffer.
-48- WO 00/12089 PCT/US99/05297 B. VEGF receptor kinase assay 1. Add 5 pl of inhibitor or control to the assay in
DMSO.
2. Add 35 pl of reaction mix containing 5 gl of 10 X reaction buffer, 5 pl 25 mM ATP/10 pCi 3 3P]ATP (Amersham), and gl 10 X substrate.
3. Start the reaction by the addition of 10 pl of KDR nM) in enzyme dilution buffer.
4. Mix and incubate at room temperature for 15 minutes.
5. Stop by the addition of 50 pl stop solution.
6. Incubate for 15 minutes at 4 0
C.
7. Transfer a 90 gl aliquot to filter plate.
8. Aspirate and wash 3 times with wash solution.
9. Add 30 gl of scintillation cocktail, seal plate and count in a Wallac Microbeta scintillation counter.
Human Umbilical Vein Endothelial Cell Mitogenesis Assay Expression of VEGF receptors that mediate mitogenic responses to the growth factor is largely restricted to vascular endothelial cells. Human umbilical vein endothelial cells (HUVECs) in culture proliferate in response to VEGF treatment and can be used as an assay system to quantify the effects of KDR kinase inhibitors on VEGF stimulation. In the assay described, quiescent HUVEC monolayers are treated with vehicle or test compound 2 hours prior to addition of VEGF or basic fibroblast growth factor (bFGF). The mitogenic response to VEGF or bFGF is determined by measuring the incorporation of ['H]thymidine into cellular DNA.
Materials HUVECs HUVECs frozen as primary culture isolates are obtained from Clonetics Corp. Cells are maintained in Endothelial Growth -49- WO 00/12089 PCT/US99/05297 Medium (EGM; Clonetics) and are used for mitogenic assays at passages 3-7.
Culture Plates NUNCLON 96-well polystyrene tissue culture plates (NUNC #167008).
Assay Medium Dulbecco's modification of Eagle's medium containing 1 g/ml glucose (low-glucose DMEM; Mediatech) plus 10% fetal bovine serum (Clonetics).
Test Compounds Working stocks of test compounds are diluted serially in 100% dimethylsulfoxide (DMSO) to 400-fold greater than their desired final concentrations. Final dilutions to IX concentration are made directly into Assay Medium immediately prior to addition to cells.
Growth factors Solutions of human VEGFI65 (500 ng/ml; R&D Systems) and bFGF (10 ng/ml; R&D Systems) are prepared in Assay Medium.
3 H]Thymidine [Methyl- 3 H]Thymidine (20 Ci/mmol; Dupont-NEN) is diluted to 80 uCi/ml in low-glucose DMEM.
Cell Wash Medium Hank's balanced salt solution (Mediatech) containing 1 mg/ml bovine serum albumin (Boehringer-Mannheim).
Cell Lysis Solution 1 N NaOH, 2% Na 2
CO
3 WO 00/12089 PCT/US99/05297 Method 1. HUVEC monolayers maintained in EGM are harvested by trypsinization and plated at a density of 4000 cells per 100 ul Assay Medium per well in 96-well plates. Cells are growth-arrested for 24 hours at 37°C in a humidified atmosphere containing 5% CO 2 2. Growth-arrest medium is replaced by 100 ul Assay Medium containing either vehicle (0.25% DMSO) or the desired final concentration of test compound. All determinations are performed in triplicate. Cells are then incubated at 37 0 C/5% CO, for 2 hours to allow test compounds to enter cells.
3. After the 2-hour pretreatment period, cells are stimulated by addition of 10 ul/well of either Assay Medium, 10X VEGF solution or bFGF solution. Cells are then incubated at 37°C/5% CO 2 4. After 24 hours in the presence of growth factors, 3 H]Thymidine (10 ul/well) is added.
Three days after addition of 3 H]thymidine, medium is removed by aspiration, and cells are washed twice with Cell Wash Medium (400 ul/well followed by 200 ul/well). The washed, adherent cells are then solubilized by addition of Cell Lysis Solution (100 ul/well) and warming to 37C for 30 minutes. Cell lysates are transferred to 7-ml glass scintillation vials containing 150 ul of water. Scintillation cocktail ml/vial) is added, and cell-associated radioactivity is determined by liquid scintillation spectroscopy.
Based upon the foregoing assays the compounds of formula I are inhibitors of VEGF and thus are useful for the inhibition of neoangiogenesis, such as in the treatment of occular disease, e.g., diabetic retinopathy and in the treatment of cancers, solid tumors.
The instant compounds inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with ICs 0 values between 150-650 nM. These compounds also show selectivity over related tyrosine kinases FGFR1 and the Src family).
-51
Claims (29)
1. A compound in accordance with formula Ia: R2 N R 5 X R 1 Ia or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein X is N or CH; R 1 is phenyl, thienyl, or thiazolyl, said phenyl, thienyl and thiazolyl is optionally to substituted with one to three members selected from Ra; R 3 is H, C-o10 alkyl, C3-6 cycloalkyl, CS- 1 0 aryl, halo, OH, C 3 heterocyclyl, or C 5 1 0 heteroaryl; said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; R 2 is independently H, C1- 6 alkyl, C 5 10 aryl, C3- 6 cycloalkyl, NO 2 -NH 2 or halogen; R 4 is phenyl, pyridinyl, pyridinyl N-oxide, pyridinone, pyrimidinyl, or a pyrimidinone, optionally substituted with one to three members selected from R; R 5 is H, Cl.1o alkyl, C 3 6 cycloalkyl, C, 6 alkoxy C 2 1 0 alkenyl, C 2 lo alkynyl, Cso aryl, C3- 10 heterocyclyl, C-6 alkoxyNR 7 Rg, halo, NO 2 OH, -NH 2 or C5- 10 heteroaryl, said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R a R is H, Cl,10 alkyl, halogen, NO 2 R, NHC,.6 alkylR 9 OR, -NR, RNR 7 R 8 NR 7 R g R 7 R 8 CN, C 5 1 0 aryl, C5-sl heteroaryl or C3-10 heterocyclyl; R is H, C, 6 alkyl or C,_ 6 alkylRg; o.OO. R 9 is Cs 5 1 0 aryl, C3- 1 heterocyclyl, or C 5 1 o heteroaryl said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R a and 0o 53 R 7 &R 8 are independently H, CI-10 alkyl, C3_ 6 cycloalkyl, COR, C 5 1 0 aryl, C 3 1 0 heterocyclyl, or C 5 -10 heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R", or NR 7 R 8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, O and S.
2. A compound in accordance with claim 1 wherein X is C and all other variables are as described in claim 1.
3. A compound in accordance with claim 1 wherein X is N and all other variables are as described in claim 1.
4. A compound in accordance with claim 1 wherein: R is H, Ci-lo alkyl, halogen, CI-6 alkylR 9 CN, R, OR, NR, RNR 7 R 8 NR 7 R 8 R 7 R 8 and all other variables are as described in claim 1. A compound in accordance with claim 1 wherein is R 3 is H, Ci- 1 0 alkyl, Cs 5 1 0 aryl, C3- 10 heterocyclyl, or C5-lo heteroaryl; said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; R 2 is independently H, C,. 6 alkyl, C3 6 cycloalkyl, OH, or halogen; R 5 is H, alkyl, C 3 6 cycloalkyl, C5- 1 0 aryl, Cso 1 heteroaryl, C3-1o heterocyclyl, C,-6 alkoxyNR 7 R 8 NO 2 OH, -NH 2 or said alkyl, aryl, heteroaryl and heterocyclyl being a optionally substituted with from one to three members selected from R and all other variables are as described above.
6. A compound in accordance with claim 5 wherein: 3s R is C 5 0 aryl, C3-lo heterocyclyl, or C 5 -1o heteroaryl; said aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from a R; R 2 is H or C,_ 6 alkyl; and all other variables are as described in claim 1.
7. A compound of the structural formula *oX .Oy Lib\LIBXX] 544692spei.d :aak or a pharmaceutically acceptable salt, hydrate or prodrug thereof, X is N or C; R, is phenyl, thienyl, or thiazolyl, said phenyl, thienyl and thiazolyl is optionally a substituted with one to three members selected from R; R2&R3 are independently H, C-6 alkyl, C 5 1 0 aryl, C3- 6 cycloalkyl, OH, NO 2 -NH,, or halogen; R 4 is phenyl, pyridinyl, pyridinyl N-oxide, pyridinone, pyrimidinyl, or a pyrimidinone, optionally substituted with one to three members selected from R; R, is H, or C1-6 alkyl, OR, halo, NH 2 or NO 2 R is H, C,,o 1 alkyl, halogen, NO,, OR, -NR, NR 7 R 8 R 7 Rg, C5- 1 0 aryl, C 5 1 0 heteroaryl or C3- 10 heterocyclyl, R is H, or C,.6 alkyl, C1- 6 alkylR 9 15 R 9 is C5. 1 0 aryl, C3-10 heterocyclyl, or C 5 10 heteroaryl; and R,&Rg are independently H, Ci.o 1 alkyl, C3- 6 cycloalkyl, COR, C 5 1 0 aryl, C3. 1 0 heterocyclyl, or C5- 1 0 heteroaryl or NR 7 R 8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, /one to two additional heteroatoms selected from the group consisting of N, O and S.
8. A compound in accordance with claim 7 wherein X is C and all other variables are as described in claim 7.
9. A compound in accordance with claim 7 wherein X is N and all other Svariables are as described in claim 7. A compound in accordance with claim 7 wherein: 25 R 2 &R 3 are independently H, C 1 -6 alkyl, C 3 6 cycloalkyl, OH, or halogen; and all other variables are as described in claim 7.
11. A compound in accordance with claim 7 wherein: R 2 &R 3 are independently H or C 1 -6 alkyl; f ad all other variables are as described in claim 7. [I:\DayLib\LIBXX]544692specidoc:aak
12. A compound of the structural formula IIa R2 N X\ R1 IIa or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein X W are independently N or C; R, is phenyl, thienyl, or thiazolyl, said phenyl, thienyl and thiazolyl is optionally substituted with one to three members selected from Ra; R 3 is H, Co 1 0 alkyl, C3- 6 cycloalkyl, C 5 1 0 aryl, halo, OH, C 3 1 0 heterocyclyl, or C 5 1 o heteroaryl; said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R a R 2 is independently H, C 6 alkyl, C 5 1 0 aryl, C 3 6 cycloalkyl, OH, NO 2 -NH2, or halogen; 15 R 5 is independently H, Cl.lo alkyl, C 3 6 cycloalkyl, C 1 6 alkoxy C2- 10 alkenyl, C2- 10 alkynyl, C 5 1 0 aryl, C3- 10 heterocyclyl, C 1 -6 alkoxyNR 7 R 8 halo, NO 2 OH, -NH 2 or C5- 10 heteroaryl, said alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from R a Rio is H, or C 6 alkyl, C,.6 alkylR, Cs 5 1 0 aryl, C 3 10 heterocyclyl, NHC 1 6 alkylR 9 said alkyl (where R is C, 6 alkyl), aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra; Ra is H, C 1 1 0 alkyl, halogen, NO 2 OR, -NR, RNR7R, NR 7 R 8 R 7 R 8 CN, Cs 1 0 aryl, Cs 5 0 heteroaryl or C 3 1 heterocyclyl; R is H, C 1 -6 alkyl or C, 1 6 alkylR 9 25 R 9 is C5-,1 aryl, C3-10 heterocyclyl, or Cs.0 heteroaryl said aryl, heteroaryl and *oo heterocyclyl being optionally substituted with from one to three members selected from a s and [I:\DayLib\LIBXX]544692speci.doc:aak 56 RA 8are independently H, CI- 10 alkyl, C 3 6 cycloalkyl, COR, C 5 10 aryl, C 3 10 heterocyclyl, or C 5 10 heteroaryl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra or NR 7 R 8 can be taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, 0 and S.
13. A compound in accordance with claim 12 wherein X or W independently are CH and all other variables are as described in claim 12.
14. A compound in accordance with claim 12 wherein X or W are independently 0 N and all other variables are as described in claim 12. A compound in accordance with claim 12 wherein Rio is H, CI 1 0 alkyl, C,- 6 alkylR 9 C 5 10 aryl, C 5 10 heteroaryl, or C 3 10 heterocyclyl, said alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with from one to three members selected from Ra and all other variables are as described in claim 12.
16. A compound in accordance with claim 1 which is: 1 -phenyl-5 4 -methoxyphenyl)benzimidazole, 1 -phenyl-5-(4-(2-( 1 -piperidinyl)ethoxy)phenyl)benzimidazole, 3 -phenyl-6-(4-methoxyphenyl)imidazo[4,5-b]pyridine, 3 -phenyl-6-(4-(2-( 1 -piperidinyl)ethoxy)phenyl)imidazo[4,5 -blpyridine, 3 -phenyl-6-(4-(2-( 1 3-(2-thiazoyl)-6-(4-(3 1 -(2-thiazoyl)-5-(4-(3 -piperidinyl)propyl)phenyl)benzimidazole, 1 -thiophenyl)-5-(4-(3-( 1 -(3-thiophenyl)-5 -piperidinyl)propyl)phenyl)benzimidazole, 3 -thiophenyl)-6-(4-(3 -pip eridinyl)propylphenyl)imidazo [4,5 -b]pyridine, I -Phenyl-5-[5-(2-piperidin- 1 -yl-ethoxy)-pyridin-2-yl] I1 H-benzimidazole, 1 4 -Cyanophenyl)-5-[6-(2-piperidin- 1 -yl-ethoxy)-pyridin-3-yl]-I H-benzimidazole, 1 -Phenyl-5 6 -(2-piperidin- 1 -yl-ethoxy)-pyridin-3-yl]y 1 H-benzimidazole, 1 3 -Cyanophenyl)- -pip eridin- 1 -yl-ethoxy)-pyridin3yl]y 1 H-benzimidazole, 30 1 3 -Thiophene)-5 -[6-(2-piperi din- 1 -yl-ethoxy)-pyridin3yl 1 H-benzimidazole, [5-(l1 -Phenyl- IlH-benzoimidazol 5 yl pyri din2yl] (2 piperi din- 1 -yl -ethyl) -amine, [5 -Phenyl- 1 H-benzoimidazol5yl)pyridin2yl>(2-morpho 1 in- 1 -yl-ethyl)- V0006 9. S S **SS S 5* S S. amnine, S 4-(I1 -Phenyl- 1 H-benz 35 4-(1 -Phenyl-1IH-benz [1:\DayLib\LIBXX]544692specidocaak oimidazol-5 1-(3 -piperidin- 1-yl-propyl)- 1H-pyridin-2-one, oimidazol-5 -yl)-l1-( 3 -piperidin- 1-yl-ethyl)- 1H-pyridin-2-one, 57 1 -Pyridyl)-5 1 -piperidinyl)ethoxy)phenyl)benzimidazole, 1 -(4-Pyridyl)-5-(4-(2-( 1 -piperidinyl)ethoxy)phenyl)benzimidazole, 1 -(3-Pyridyl)-5-[6-(2-piperidin. I-yl-ethoxy)-pyridin-3-yl] -1H-benzimidazole, and 1 -(4-Pyridyl)-5-[6-(2-piperidin 1 -yl-ethoxy)-pyridin-3-yl] -1H-benzimidazole or a pharmaceutically acceptable salt, hydrate or prodrug thereof.
17. A compound in accordance with claim 1 which is: 1 2 -morpholin-4-yl-ethyl)-4-( 1 -phenyl- 1 H-benzoimidazol-5-yl)- I H-pyridin-2-one, 1 3 -dimethylamino-propyl)-4( 1 -phenyl- I H-benzoimidazol-5-yl)- 1 H-pyridin-2- one, 1 -methyl-piperidin-3 -ylmethyl)-4-( 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H- pyridin-2-one, 1 -[3-(4-rnethylpiperazin- I -yl)-propyl)]-4-( 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H- pyridin-2-one, 1 2 -dimethylamino-propyl)-4-( 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H-pyridin-2- one, 1 -dimethylamino-2-methyl-propyl)4( 1 -phenyl- 1 H-benzoimidazol-5 1 H- pyridin-2-one, 1- 2 -(4-cyano-piperi din- 1 -yl)-ethyl]-4-( 1 -phenyl- 1 H-benzoimidazol-5 -yl)-lI H- pyridin-2-one, 1 -(3-piperidin- 1 -yl-propyl)-4-( 1 -thiophen-3 -yl- 1 H-benzoimidazol-5-yl)- 1 H-pyridin- 2-one, S. ~1 -(3-piperidin- 1 -yl-ethyl)-4-( 1 -thiophen-3 -yl- 1 H-benzoimidazol-5 1H-pyridin- 2-one, -(2-morpholin-4-yl-ethyl)-4-( I -thiophen-3 -yl- 1 H-benzoimidazol-5 I H-pyridin- 2-one, 1 -(3-dimethylamino-propyl)-4-( I -thiophen-3-yl- 1 H-benzoimidazol-5-yl)- 1 H- pyridin-2-one, 1 -methyl-piperidin-3-ylmethyl)4( 1 -thiophen-3-yl- 1 H-benzoimidazol-5-yI)- 1 H- S 5 pyridin-2-one, 1 3 4 -methylpiperazin- 1 -yl)-propyl)] 1 -thiophen-3 -yl- 1 H-benzoimidazol-5 -yl)- I1H-pyridin-2-one, :51 2 -dimethylamino-propyl)-4-( 1 -thiophen-3 -yl- 1 H-benzoimidazol-5 1 H- pyridin-2-one, ~U 1 -dimethylamino-2-methyl..propyly4.( 1-thiophen-3-yl- 1H-benzoimidazol-5 -yl)- 58 1- 2 4 -cyano -piperi din- 1 -yl)-ethyl] 1 -thiophen-3 -yl-1I 1 H-p yridin-2-one, 5-(l1 -phenyl- 1 H-benzoimidazo-5-y>. 1 -piperidin- 1 -yl-propyl)- 1H-pyridin-2-one, 5-(l1 -phenyl- 1 H-benzoimidazol-5-y). 1 -piperidin- 1 -yl-ethyl)- 1 H-pyridin-2-one, 1 -(2-morpholin-4-yl-ethyl)$-( 1 -phenyl- 1 H-benzoimidazol-5-yly- I.1H-pyridin-2-one, 1 -dimethylamino-propyl)>5( 1 -phenyl- 1 H-benzoimidazol-5 -yI)-1I H-pyridin-2- one, 1 -methyl-piperidin-3-ylmethyl)5( 1 -phenyl- 1 H-benzoimidazol-5-yI> 1I H- pyridin-2-one, 0 1 3 -(4-methylpiperazin- 1 -yl)-propyl)]-5-( 1 -phenyl- 1 H-benzoimidazol-5-yly.. 1 H- pyridin-2-one, 1 -(2-dimethylarino-propylys( 1 -phenyl- 1 H-benzoimidazol-5-yl)- I H-pyridin-2- one, 1 3 -dimethyl am ino-2-methylprop 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H- pyridin-2-one, I 2 4 -cyano-piperidin- 1 -yl)-ethyl]-5-( 1 -phenyl- 1 H-benzoimidazol-5-yl) 1 H- pyridin-2-one, 1 -piperidin- 1 -yl-propyl)-5 -thiophen-3-yl- 1H-benzoimidazol-5 -yI)-1I H-pyridin- 2-one, 1 -(3-piperidin- 1 -yI-ethyl)-5 -thiophen-3 -yl-1 H-benzoimidazol-5 -yl)-1I H-pyridin- 2-one, 1 2 -morpholin-4-yl-ethyl)-5( 1 -thiophen-3-yI- 1 H-benzoimidazol-5-yl). 1 H-pyridin- :*Soo*2-one, 1 -dimethylamino-propyl)-5-(1 -thiophen-3-yl- 1 H-benzoimidazol-5-yl)- 1 H- pyridin-2-one, 1 -methyl-piperidin-3 -ylmethyl)-5 -thiophen-3 -yI-1I H-benzoimidazol-5-yl)- 1 H- pyridin-2 -one, 1 -1 3 4 -methylpiperazin- 1 -yI)-propyl)]-5-( 1 -thiophen-3-yl- 1 1H-pyridin-2-one, 1 -(2-dimethylamino-propyl)-5-(1 -thiophen-3-yl- 1 H-benzoimidazol-5 -yl)-l H- pyridin-2-one, 1 -dimethylamino-2-methyl-propyl).5 -thiophen-3 -yl- 1H-pyridin-2-one, s 1 -[2-(4-cyano-piperidin- 1-yl)-ethyl]-5 -thiophen-3 -yl- 1H-benzoimidazol-5 -yl)- 1H yrdin-2-one, FR:Aay~ib\LIBXXj544692specidocaak 59 5-(l1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 -piperidin- 1 -yl-propyl)-l1H-pyrimidin-2- one, -phenyl- 1 H-benzoimidazol-5-yI)- 1 -(3-piperidin- 1 -yI-ethyl)- 1 I 4 -pyrimidin-2- one, 1 -(2-morpholin-4-yl-ethyl)-5 -phenyl- 1 H-benzoimidazol-5 -yl)-1 H-pyrimidin-2- one, 1 -dimethylamino-propyl)-5 -phenyl- I H-benzoimidazol-5-yl)- 1 H-pyrimidin-2- one, 1 -methyl-piperidin-3-ylrnethyl)-5( 1 -phenyl- 1H-benzoimidazol-5-yl)- 1 H- i0 pyrirnidin-2-one, 1 -[3-(4-methylpiperazin- 1 -yl)-propyl)]-5-( 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H- pyrimidin-2-one, 1 -(2-dimethylamino-propyl)-5 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H-pyrimidin-2- one, 1 3 -dimethylamino-2-methyl-propyl)-5( 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H- pyrimidin-2-one, 1 2 -(4-cyano-piperidin- 1 -yl)-ethyl]-5-( 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1H- pyrimidin-2-one, 1 -(3-piperidin- 1 -yl-propyl)-5-( 1 -thiophen-3-yl- 1 H-benzoimidazol-5-yl)- 1 H- pyrimidin-2-one, 1 -(3-piperidin- 1 -yl-ethyl)-5-( 1 -thiophen-3-yl- 1 H-benzoimidazol-5-yl)- 1H- pyrimidin-2-one, 1 -(2-morpholin-4-yl-ethyl)-5-( 1-thiophen-3-yl- 1H-benzoimidazol-5 -yI)-lH- 9. 9.pyrimidin-2-one, 1 -(3-dimethylamino-propyl)-5-( 1-thiophen-3-yl- 1H-benzoimidazol-5 -yl)-l H- pyrimidin-2-one, 1 -methyl-piperidin-3-ylmethyl)5-( 1-thiophen-3-yl- 1H-benzoimidazol-5-yI)- 1H- pyrimidin-2-one, I -[3-(4-methylpiperazin- 1-yl)-propyl)]-5-( I-thiophen-3-yl- 1H-pyrimidin-2-one, 1 -(2-dimethylamino-propyl)-s -thiophen-3-yl- 1H-benzoimidazol-5 -yl)-l H- pyrimidin-2-one, 9 ~1 -dimethylamino-2-methyl-propyl).5-( 1-thiophen-3 -yl-1 H-benzoimidazol-5 -yl)- S~1I{pyrimidin-2-one, [1:\DayLib\LIBXXIS44692specidoc:aak 1 2 -(4-cyano-piperidin- 1 -yl)-ethyl]-5-( 1 -thiophen-3 -yl-lI 1 H-pyrimidin-2-one, 1 -phenyl- 1 H-benzoimidazol-5 -yl)-l1 -piperidin- 1 -yl-propyl)- 1 H-pyrimidin-2- one, 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 -pipenidin- 1 -yI-ethyl)- 1 H-pyrimidin-2- one, I -(2-morpholin-4-yl-ethyly4( 1 -phenyl- 1 H-benzoimidazol-5 -yl)-lI H-pyrimidin-2- one, 1 -dimethylamino-propyl)>4( 1 -phenyl- 1 H-benzoimidazol-5-yl)- 1 H-pyrimidin-2- one, 1 -rnethyl-piperidin-3 -ylrnethyl)A4( 1 -phenyl- 1 H-benzoimidazol-5 1 H- pyrimidin-2-one, 1 4 -methylpiperazin- 1 -yl)-propyl)] 1 -phenyl- 1 H-benzoimidazol-5 -yl)-1I H- pyrimidin-2-one, 1 -(2-dimethylamino-propyl)-4( 1 -phenyl- 1 H-benzoimidazol-5 1 H-pyrimidin-2- one, 1 3 -dimethylamino-2-methylpropyl)4( 1 -phenyl- 1 H-benzoimidazol-5 1 H- pyrimidin-2-one, 1 2 4 -cyano-piperidin- 1 -yl) -ethyl] 1 -phenyl- 1 H-benzoimidazol-5 1 H- pyrimidin-2-one, 1 -piperidin- 1 -yl-propyl)-4-( 1 -thiophen-3 -yl- 1 H-benzoimidazol-5 1 H- pyrimidin-2-one, 1 -(3-piperidin- 1-yI-ethyl)-4-( 1-thiophen-3 -yl-l H-benzoimidazol-5-yl)- 1H- pyrimidin-2-one, 1 2 -morpholin-4-yl-ethyl)-4-( 1-thiophen-3-yl- 1H-benzoimidazol-5-yI)- 1H- pyrimidin-2-one, 1 -(3-dimethylamino-propyl)-4-( 1-thiophen-3-yl- 1H-benzoimidazol-5-yl)- 1H- pyrirnidin-2-one, 1 -methyl-piperidin-3-ylmethyl)4-( 1-thiophen-3-yl-l1H-benzoimidazol-5-yl)- IH- pyrlimilun-L-one, 1- [3 -(4-methylpiperazin- 1 -yl)-p ropyl)] 1 -thiophen-3 -yl- 1 H-benzoimidazol-5 -yl)- 1 H-pyrimidin-2-one, 1 -(2-dimethylamino-propyl)-4.( 1-thiophen-3-yl- 1H-benzoimidazol-5 -yl)-l H- im 7 q idin- -one, OPT'FayLib\LIBXX544692spcidocaak 61 1-(3-dimethylamino-2-methyl-propyl)-4-( -thiophen-3-yl-1H-benzoimidazol-5-yl)- 1H-pyrimidin-2-one, 1 -[2-(4-cyano-piperidin-1 -yl)-ethyl]-4-(1 -thiophen-3-yl-1 1H-pyrimidin-2-one or a pharmaceutically acceptable salt, hydrate or prodrug thereof. s 18. A pharmaceutical composition which is comprised of a compound in accordance with claim 1 or a pharmaceutically acceptable salt, prodrug or hydrate thereof in combination with a carrier.
19. A method of treating or preventing cancer in a mammalian patient in need of such treatment which is comprised of administering to said patient an anti-cancer to effective amount of a compound of claim 1. A method of treating or preventing cancer in accordance with claim 19 wherein the cancer comprises cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.
21. A method in accordance with claim 19 wherein the cancer comprises histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, gioblastomas and breast carcinoma.
22. A method of treating or preventing a disease in which neoangiogenesis is implicated, which is comprised of administering to a mammalian patient in need of such treatment a compound of claim 1 or a pharmaceutically acceptable salt, prodrug or hydrate thereof in an amount which is effective for reducing neoangiogenesis.
23. A method in accordance with claim 22 wherein the disease is an ocular "disease.
24. A method of treating or preventing retinal vascularization which is comprised of administering to a mammalian patient in need of such treatment a compound of claim 1 or a pharmaceutically acceptable salt, prodrug or hydrate thereof in an amount which is effective for treating retinal vascularization. A method of treating or preventing diabetic retinopathy which is comprised of administering to a mammalian patient in need of such treatment a compound of claim 1 or o a pharmaceutically acceptable salt, prodrug or hydrate thereof in an amount which is 30 effective for treating diabetic retinopathy.
26. A method of treating or preventing age-related macular degeneration which is 0.0. comprised of administering to a mammalian patient in need of such treatment a compound of claim 1 or a pharmaceutically acceptable salt, prodrug or hydrate thereof in C anmamount which is effective for inflammation. O 1\[I i yLib\LIBXX]544692speci.doc:aak 62
27. A method of treating or preventing inflammatory diseases which is comprised of administering to a mammalian patient in need of such treatment a compound of claim 1 or a pharmaceutically acceptable salt, prodrug or hydrate thereof in an amount which is effective for inflammation.
28. A method according to claim 27 wherein the inflammatory disease comprises rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypertensitivity reactions.
29. A method for inhibiting tyrosine kinase which comprises administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of claim 1. 0o 30. A compound as defined in any one of claims 1, 7 or 12 and substantially as herein described with reference to any one of Examples 1 to
31. A pharmaceutical composition for treating or preventing a condition selected from the group consisting of cancer, preventing a disease in which neoangiogenesis is implicated, retinal vascularization, diabetic retinopathy, age-related macular degeneration, inflammatory diseases and inhibiting tyrosine kinase, which composition comprises a compound as defined in claim 30 together with a pharmaceutically acceptable carrier.
32. A process of making a compound as defined in claim 1, 7 or 12 which process is substantially as herein described with reference to any one of Examples 1 to
33. A compound as defined in any one of claims 1 to 17 or 30 when used in a therapeutic amount to prevent or treat a condition selected from the group consisting of o* cancer, preventing a disease in which neoangiogenesis is implicated, retinal S, vascularization, diabetic retinopathy, age-related macular degeneration, inflammatory *diseases and inhibiting tyrosine kinase, in a mammalian patient in need thereof.
34. A pharmaceutical composition as defined in claim 18 or 31 when used in a therapeutic amount to prevent or treat a condition selected from the group consisting of cancer, preventing a disease in which neoangiogenesis is implicated, retinal vascularization, diabetic retinopathy, age-related macular degeneration, inflammatory diseases and inhibiting tyrosine kinase, in a mammalian patient in need thereof.
35. A method of treating or preventing a condition selected from the group 30 consisting of cancer, preventing a disease in which neoangiogenesis is implicated, retinal vascularization, diabetic retinopathy, age-related macular degeneration, inflammatory diseases and inhibiting tyrosine kinase, in a mammalian patient in need thereof, said method comprising administering to said mammal a therapeutically effective amount of a I compound of claim 30 or a therapeutically effective amount of a composition of claim 31. :\DayLib\LIBXX]544692speci.doc:aak 63
36. The method of any one of claims 19 to 29 or 35 wherein the mammalian patient is a human. Dated 25 February, 2003 Merck Co., Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON :foe* a 6 :*foe [1:\DayLib\LIBXX]544692speci.doc:aak
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14388198A | 1998-08-31 | 1998-08-31 | |
| US09/143881 | 1998-08-31 | ||
| PCT/US1999/005297 WO2000012089A1 (en) | 1998-08-31 | 1999-03-11 | Novel angiogenesis inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3078999A AU3078999A (en) | 2000-03-21 |
| AU760020B2 true AU760020B2 (en) | 2003-05-08 |
Family
ID=22506085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU30789/99A Expired - Fee Related AU760020B2 (en) | 1998-08-31 | 1999-03-11 | Novel angiogenesis inhibitors |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1109555A4 (en) |
| JP (1) | JP2002523459A (en) |
| AU (1) | AU760020B2 (en) |
| CA (1) | CA2341409A1 (en) |
| WO (1) | WO2000012089A1 (en) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1132381A1 (en) * | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
| DE10021246A1 (en) * | 2000-04-25 | 2001-10-31 | Schering Ag | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis |
| US6756383B2 (en) * | 2000-09-01 | 2004-06-29 | Chiron Corporation | Heterocyclic derivatives of quinolinone benimidazoles |
| CN1307173C (en) | 2000-12-21 | 2007-03-28 | 葛兰素集团有限公司 | Pyrimidineamines as angiogenesis modulators |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| RU2259825C9 (en) | 2001-06-18 | 2006-04-10 | БиоДием Лимитед | Substances of antimicrobial, antifungoid and antiprotozoan activities |
| CA2477505A1 (en) * | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| WO2004014899A1 (en) * | 2002-08-08 | 2004-02-19 | Smithkline Beecham Corporation | Thiophene compounds |
| AU2003291226B2 (en) * | 2002-11-01 | 2009-06-04 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| FR2846656B1 (en) * | 2002-11-05 | 2004-12-24 | Servier Lab | NOVEL IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| MXPA06000508A (en) | 2003-07-18 | 2006-04-05 | Amgen Inc | Specific binding agents to hepatocyte growth factor. |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| MXPA06002017A (en) | 2003-08-21 | 2006-05-31 | Osi Pharm Inc | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors. |
| US7442709B2 (en) | 2003-08-21 | 2008-10-28 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine c-Kit inhibitors |
| JP2007509070A (en) | 2003-10-16 | 2007-04-12 | スミスクライン ビーチャム コーポレーション | Thiophene compound |
| US20050107374A1 (en) * | 2003-10-21 | 2005-05-19 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2005075470A1 (en) | 2004-01-28 | 2005-08-18 | Smithkline Beecham Corporation | Thiazole compounds |
| GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402809D0 (en) * | 2004-02-09 | 2004-03-10 | Glaxo Group Ltd | Chemical compounds |
| JP2008504233A (en) | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | Transcription factor modulating compounds and methods of use thereof |
| CN101006078A (en) | 2004-06-17 | 2007-07-25 | 惠氏公司 | Gonadotropin releasing hormone receptor antagonists |
| BRPI0512239A (en) | 2004-06-17 | 2008-02-19 | Wyeth Corp | processes for preparing gonatropin-releasing hormone receptor antagonists |
| EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| BRPI0610514A2 (en) * | 2005-04-05 | 2016-11-16 | Pharmacopeia Inc | compound, pharmaceutical composition, and method of treating a disorder |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| PT1937671E (en) | 2005-09-06 | 2010-03-12 | Smithkline Beecham Corp | Benzimidazole thiophene compounds as plk inhibitors |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (en) | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
| WO2007092178A1 (en) | 2006-02-10 | 2007-08-16 | Amgen Inc. | Hydrate forms of amg706 |
| US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| AR059898A1 (en) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS |
| US7615643B2 (en) | 2006-06-02 | 2009-11-10 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds |
| PE20121506A1 (en) | 2006-07-14 | 2012-11-26 | Amgen Inc | TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| AR063141A1 (en) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION |
| JP2010511635A (en) * | 2006-12-04 | 2010-04-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Inhibitors of HIV replication |
| CA2672438A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| AU2007337895C1 (en) | 2006-12-22 | 2014-07-31 | Astex Therapeutics Limited | Tricyclic amine derivatives as protein tyrosine kinase inhibitors |
| WO2008078091A1 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
| US7759344B2 (en) | 2007-01-09 | 2010-07-20 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
| JP2010519204A (en) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | Nitrogen-containing heterocyclic ketones and their use as c-Met inhibitors |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| BRPI0815368A2 (en) | 2007-08-21 | 2015-02-10 | Amgen Inc | "HUMAN ANTIGEN C-FMS PROTEINS" |
| EP2203439B1 (en) | 2007-09-14 | 2011-01-26 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| MX2011002042A (en) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors. |
| RU2512283C2 (en) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| CN102439008B (en) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| EA020671B1 (en) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
| JP5852665B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
| US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| MY161199A (en) | 2011-03-23 | 2017-04-14 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| ES2860298T3 (en) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use |
| MY182627A (en) | 2014-01-21 | 2021-01-27 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| WO2016112111A1 (en) | 2015-01-08 | 2016-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| WO2017024406A1 (en) | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| KR20180039117A (en) | 2015-08-11 | 2018-04-17 | 네오메드 인스티튜트 | Aryl-substituted dihydroquinolinone, its preparation and its use as a pharmaceutical |
| AU2016305515A1 (en) | 2015-08-12 | 2018-03-08 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| SG11201906223TA (en) | 2016-12-22 | 2019-08-27 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| JP7361722B2 (en) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | KRAS G12C inhibitors and methods of using the same |
| MA52501A (en) | 2018-05-04 | 2021-03-10 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| AU2019278998B2 (en) | 2018-06-01 | 2023-11-09 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MX2020012261A (en) | 2018-06-12 | 2021-03-31 | Amgen Inc | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer. |
| JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| CA3123871A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3898592A1 (en) | 2018-12-20 | 2021-10-27 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| MX2021007104A (en) | 2018-12-20 | 2021-08-11 | Amgen Inc | Kif18a inhibitors. |
| MA54546A (en) | 2018-12-20 | 2022-03-30 | Amgen Inc | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS |
| US20230148450A9 (en) | 2019-03-01 | 2023-05-11 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| CN113727758A (en) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | Bicyclic heterocyclic compounds and use thereof |
| US11465998B2 (en) | 2019-04-25 | 2022-10-11 | Regents Of The University Of Minnesota | Therapeutic compounds and methods of use thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
| CN114391012A (en) | 2019-08-02 | 2022-04-22 | 美国安进公司 | Pyridine derivatives as KIF18A inhibitors |
| JP2022542967A (en) | 2019-08-02 | 2022-10-07 | アムジエン・インコーポレーテツド | KIF18A inhibitor |
| JP2022542394A (en) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Heteroarylamides useful as KIF18A inhibitors |
| MX2022001296A (en) | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
| WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| KR20220109407A (en) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | RAS inhibitors |
| PE20221278A1 (en) | 2019-11-04 | 2022-09-05 | Revolution Medicines Inc | RAS INHIBITORS |
| BR112022008534A2 (en) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATE AND METHODS TO TREAT CANCER AND TO TREAT A RAS PROTEIN-RELATED DISORDER |
| CR20220200A (en) | 2019-11-08 | 2022-07-28 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
| BR112022009390A2 (en) | 2019-11-14 | 2022-08-09 | Amgen Inc | IMPROVED SYNTHESIS OF KRAS INHIBITOR COMPOUND G12C |
| WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| CN114980976A (en) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
| CA3163703A1 (en) | 2020-01-07 | 2021-07-15 | Steve Kelsey | Shp2 inhibitor dosing and methods of treating cancer |
| EP4168002A1 (en) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022140427A1 (en) | 2020-12-22 | 2022-06-30 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN117616031A (en) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | RAS inhibitors for the treatment of cancer |
| AU2022270116A1 (en) | 2021-05-05 | 2023-12-21 | Revolution Medicines, Inc. | Ras inhibitors |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2637731A (en) * | 1949-06-02 | 1953-05-05 | American Cyanamid Co | Imidazopyridines |
| US3819640A (en) * | 1972-08-07 | 1974-06-25 | Degussa | Aza-benzimidazoles and process for their production |
| SE422799B (en) * | 1975-05-28 | 1982-03-29 | Merck & Co Inc | ANALOGY PROCEDURE FOR PREPARATION OF 1,3-DIHYDROIMIDAZO (4,5-B) PYRIDIN-2-ONER |
| US4859672A (en) * | 1986-10-29 | 1989-08-22 | Rorer Pharmaceutical Corporation | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone |
| FR2643903A1 (en) * | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS |
| US5010086A (en) * | 1990-02-28 | 1991-04-23 | Sterling Drug Inc. | Imidazopyridines, compositions and use |
| US5248672A (en) * | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
| EP0581955B1 (en) * | 1992-02-13 | 1996-10-16 | MERCK PATENT GmbH | Use of benzimidazole derivatives as protective light filters |
| DK40192D0 (en) * | 1992-03-26 | 1992-03-26 | Neurosearch As | IMIDAZOLE COMPOUNDS, THEIR PREPARATION AND USE |
| GB9210400D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
| CA2131134A1 (en) * | 1993-09-17 | 1995-03-18 | Gerhard Stucky | Process for preparing imidazopyridine derivatives |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US5637724A (en) * | 1995-06-05 | 1997-06-10 | Neurogen Corporation | Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands |
| CA2283961A1 (en) * | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
| AU734009B2 (en) * | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
-
1999
- 1999-03-11 CA CA002341409A patent/CA2341409A1/en not_active Abandoned
- 1999-03-11 AU AU30789/99A patent/AU760020B2/en not_active Expired - Fee Related
- 1999-03-11 EP EP99912408A patent/EP1109555A4/en not_active Withdrawn
- 1999-03-11 JP JP2000567206A patent/JP2002523459A/en not_active Withdrawn
- 1999-03-11 WO PCT/US1999/005297 patent/WO2000012089A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3078999A (en) | 2000-03-21 |
| WO2000012089A1 (en) | 2000-03-09 |
| JP2002523459A (en) | 2002-07-30 |
| CA2341409A1 (en) | 2000-03-09 |
| EP1109555A4 (en) | 2001-11-21 |
| EP1109555A1 (en) | 2001-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU760020B2 (en) | Novel angiogenesis inhibitors | |
| US6465484B1 (en) | Angiogenesis inhibitors | |
| US6162804A (en) | Tyrosine kinase inhibitors | |
| AU744939B2 (en) | Novel angiogenesis inhibitors | |
| US6235741B1 (en) | Angiogenesis inhibitors | |
| AU734009B2 (en) | Novel angiogenesis inhibitors | |
| AU2010341573B2 (en) | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | |
| AU2006223070B2 (en) | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | |
| AU2009281822B2 (en) | cMET inhibitors | |
| CA2336848A1 (en) | Novel angiogenesis inhibitors | |
| JP5255438B2 (en) | Benzimidazoles useful as protein kinase inhibitors | |
| KR20030040419A (en) | Fused pyrazole derivatives being protein kinase inhibitors | |
| CZ297534B6 (en) | Pyridazine derivatives exhibiting inhibiting activity to angiogenesis, process of their preparation, their use and pharmaceutical compositions in which the derivatives are comprised | |
| AU2013292841A1 (en) | N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof | |
| EA019507B1 (en) | Fused nitrogen containing heterocycles and compounds thereof as kinase inhibitors | |
| AU2011216895A1 (en) | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | |
| JP2011525535A (en) | PI3K / mTOR inhibitor | |
| EP1147107A1 (en) | Novel angiogenesis inhibitors | |
| US20040132730A1 (en) | Inhibitors of TGFbeta | |
| US6380203B1 (en) | Angiogenesis inhibitors | |
| WO2022237676A1 (en) | Preparation and application of shp2 phosphatase inhibitor | |
| KR20210083293A (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| US6228871B1 (en) | Angiogenesis inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |